Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Neurocrine Biosciences, Inc. (NBIX)
USD170.70
-3.40 (-1.95%)
US NASDAQ Healthcare Biotechnology
Address
12780 El Camino Real 92130
San Diego, CA, US
San Diego, CA, US
CEO
Kyle W. Gano
Website
neurocrine.com
IPO
1996-05-23
CIK 914475 ISIN US64125C1099
Also trades on
London Stock Exchange · 0K6R.L (USD)
NASDAQ Global Select · NBIX (USD)
Description
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
News Sentiment (7d)
4 articles
- 3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) Zacks Investment Research
- Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline FXEmpire
- Why Crinetics Stock Soared 99% This Week 24/7 Wall Street
- Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results PRNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD170.70
-3.40 (-1.95%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.40
Float Shares
99.08M
Free Float %
98.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.09% | +3.07% | +16.84% | +22.33% | +2.55% | +6.18% | +25.04% | +55.71% | +63.42% | +250.70% | +1,104.72% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (37 ratings, all time)
Buy
Price Targets & DCF
Current price
170.70
Low
140.00
-18.0%
Consensus
181.33
+6.2%
Median
181.50
+6.3%
High
230.00
+34.7%
DCF (Unlevered)
508.81
+198.1%
DCF (Levered)
682.03
+299.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
85% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 19 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
220.00
+28.9%
|
| Last Quarter | 9 |
177.00
+3.7%
|
| Last Year | 28 |
176.25
+3.3%
|
| All Time | 64 |
157.53
-7.7%
|
Quality scores
Altman Z-Score
7.89
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Biotechnology: +1.6%+21.5% ★ Q1'26: +42.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+42.0% ★ Q1'26: +2,287.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+9.8% Q1'26: +16.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+22.3% ★ Q1'26: +22.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+19.7% ★ Q1'26: +23.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.2% ★ Q1'26: +0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.62× ★ Q1'26: 0.53× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 15 Rev. Ana. 11 EPS Ana. |
Dec 2027 14 Rev. Ana. 10 EPS Ana. |
Dec 2028 13 Rev. Ana. 13 EPS Ana. |
Dec 2029 12 Rev. Ana. 11 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
33.50M
est: 35.42M (-5.4%)
|
77.41M
est: 55.98M (+38.3%)
|
53.14M
est: 64.87M (-18.1%)
|
2.92M
est: 3.13M (-6.9%)
|
19.77M
est: 20.32M (-2.7%)
|
15.00M
est: 15.00M (+0.0%)
|
161.63M
est: 153.59M (+5.2%)
|
451.20M
est: 452.49M (-0.3%)
|
788.10M
est: 776.32M (+1.5%)
|
1.05B
est: 1.06B (-0.9%)
|
1.13B
est: 1.14B (-0.3%)
|
1.49B
est: 1.48B (+0.3%)
|
1.89B
est: 2.12B (-11.0%)
|
2.36B
est: 2.36B (-0.1%)
|
2.86B
est: 2.84B (+0.6%)
|
3.69B
3.46B – 3.86B
+29.7% YoY
|
4.27B
3.47B – 5.37B
+15.7% YoY
|
4.77B
4.65B – 4.89B
+11.8% YoY
|
5.02B
4.41B – 5.75B
+5.2% YoY
|
5.43B
4.77B – 6.22B
+8.2% YoY
|
| EBITDA |
-12.29M
est: -10.53M (-16.7%)
|
34.62M
est: 37.32M (-7.3%)
|
2.11M
est: 28.47M (-92.6%)
|
-49.01M
est: -48.32M (-1.4%)
|
-87.92M
est: -71.85M (-22.4%)
|
-139.64M
est: -164.37M (+15.0%)
|
-120.62M
est: -98.40M (-22.6%)
|
56.30M
est: 65.73M (-14.3%)
|
85.90M
est: 233.37M (-63.2%)
|
148.10M
est: 161.82M (-8.5%)
|
138.10M
est: 174.19M (-20.7%)
|
264.60M
est: 82.53M (+220.6%)
|
416.10M
est: 783.25M (-46.9%)
|
639.70M
est: 870.83M (-26.5%)
|
666.60M
est: 1.05B (-36.6%)
|
1.36B
1.28B – 1.43B
+29.7% YoY
|
1.58B
1.28B – 1.99B
+15.7% YoY
|
1.76B
1.72B – 1.81B
+11.8% YoY
|
1.86B
1.63B – 2.12B
+5.2% YoY
|
2.01B
1.76B – 2.30B
+8.2% YoY
|
| EBIT |
-13.72M
est: -18.24M (+24.8%)
|
33.92M
est: 32.69M (+3.8%)
|
1.45M
est: 21.14M (-93.2%)
|
-49.68M
est: -52.85M (+6.0%)
|
-88.93M
est: -74.84M (-18.8%)
|
-141.09M
est: -167.97M (+16.0%)
|
-123.02M
est: -110.35M (-11.5%)
|
52.30M
est: 47.40M (+10.3%)
|
78.50M
est: 179.78M (-56.3%)
|
139.50M
est: 251.68M (-44.6%)
|
127.20M
est: 108.70M (+17.0%)
|
249.00M
est: 109.35M (+127.7%)
|
394.80M
est: 759.16M (-48.0%)
|
612.60M
est: 844.05M (-27.4%)
|
636.50M
est: 1.02B (-37.5%)
|
1.32B
1.24B – 1.38B
+29.7% YoY
|
1.53B
1.24B – 1.92B
+15.7% YoY
|
1.71B
1.67B – 1.75B
+11.8% YoY
|
1.80B
1.58B – 2.06B
+5.2% YoY
|
1.95B
1.71B – 2.23B
+8.2% YoY
|
| Net Income |
-7.97M
est: -12.10M (+34.2%)
|
37.57M
est: 36.58M (+2.7%)
|
5.03M
est: 27.31M (-81.6%)
|
-46.09M
est: -49.03M (+6.0%)
|
-88.93M
est: -69.56M (-27.8%)
|
-141.09M
est: -160.73M (+12.2%)
|
-142.54M
est: -126.87M (-12.3%)
|
21.11M
est: 32.83M (-35.7%)
|
37.00M
est: 161.93M (-77.2%)
|
407.30M
est: 1.32B (-69.1%)
|
89.60M
est: 110.42M (-18.9%)
|
154.50M
est: 4.14M (+3,635.8%)
|
249.70M
est: 339.20M (-26.4%)
|
341.30M
est: 474.21M (-28.0%)
|
478.60M
est: 528.41M (-9.4%)
|
789.06M
648.35M – 929.78M
+49.3% YoY
|
1.11B
736.78M – 1.21B
+40.2% YoY
|
1.42B
672.50M – 2.05B
+28.5% YoY
|
1.31B
1.10B – 1.55B
-8.0% YoY
|
1.52B
1.28B – 1.81B
+16.5% YoY
|
| SGA |
16.07M
est: 17.02M (-5.6%)
|
12.46M
est: 13.30M (-6.4%)
|
13.44M
est: 26.23M (-48.8%)
|
13.35M
est: 1.46M (+813.1%)
|
32.48M
est: 9.48M (+242.6%)
|
68.08M
est: 7.00M (+872.9%)
|
169.91M
est: 71.65M (+137.1%)
|
248.93M
est: 232.69M (+7.0%)
|
354.10M
est: 514.84M (-31.2%)
|
433.30M
est: 492.42M (-12.0%)
|
583.30M
est: 858.22M (-32.0%)
|
752.70M
est: 1.23B (-39.0%)
|
887.60M
est: 984.46M (-9.8%)
|
1.01B
est: 1.09B (-8.0%)
|
1.16B
est: 1.32B (-12.5%)
|
1.71B
1.61B – 1.79B
+29.7% YoY
|
1.98B
1.61B – 2.50B
+15.7% YoY
|
2.22B
2.16B – 2.27B
+11.8% YoY
|
2.33B
2.05B – 2.67B
+5.2% YoY
|
2.52B
2.22B – 2.89B
+8.2% YoY
|
| EPS |
-0.15
est: -0.44 (+65.5%)
|
0.68
est: 0.33 (+106.1%)
|
0.08
est: -0.38 (+120.4%)
|
-0.69
est: -0.79 (+12.7%)
|
-1.05
est: -1.07 (+1.4%)
|
-1.63
est: -1.67 (+2.7%)
|
-1.62
est: -1.52 (-6.5%)
|
0.22
est: 0.22 (+1.7%)
|
0.40
est: 0.83 (-52.0%)
|
4.37
est: 1.20 (+264.8%)
|
0.95
est: 1.78 (-46.7%)
|
1.61
est: 2.22 (-27.4%)
|
2.56
est: 3.42 (-25.2%)
|
3.40
est: 3.95 (-14.0%)
|
4.81
est: 5.04 (-4.5%)
|
7.55
6.33 – 9.07
+49.9% YoY
|
9.32
7.19 – 11.81
+23.5% YoY
|
11.52
6.56 – 20.01
+23.6% YoY
|
12.77
10.75 – 15.16
+10.8% YoY
|
14.88
12.53 – 17.67
+16.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-22 | Leerink Partners | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
952.42M
OE per share TTM
9.30
Owner's Yield
7.02%
Maintenance CapEx ratio
16.86%
Maint CapEx / Avg PPE
17.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
214
Total invested
607.96M
Insider transactions (90d)
0
Beneficial owners (>5%)
21
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 13.10M | 14.43% | — | — | 13.10M | — | IN | Delaware | 2019-02-13 | ↗ |
| 2 | (1) BlackRock, Inc. | 11.48M | 12.10% | 10.97M | — | 11.48M | — | HC | Delaware | 2022-01-27 | ↗ |
| 3 | Edward C. Johnson 3d | 11.40M | 15.00% | — | — | 11.40M | — | IN | United States of America | 2015-02-13 | ↗ |
| 4 | The Vanguard Group - 23-1945930 | 8.79M | 9.26% | — | 77.1K | 8.64M | 143.2K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 5 | EIN #00-0000000 | 7.45M | 7.80% | — | 7.45M | — | 7.45M | IA, HC | Jersey, Channel Islands | 2022-02-10 | ↗ |
| 6 | Capital International Investors ** | 6.74M | 7.30% | 6.36M | — | 6.74M | — | IA | — | 2020-02-14 | ↗ |
| 7 | 2 | 5.15M | 5.60% | — | 5.15M | — | 5.15M | IA | Delaware | 2018-02-14 | ↗ |
| 8 | STATE STREET CORPORATION | 5.15M | 5.10% | — | 4.72M | — | — | HC | MA | 2024-10-17 | ↗ |
| 9 | 52-0556948 | 4.36M | 4.50% | 1.57M | — | 4.36M | — | IA | Maryland | 2022-02-14 | ↗ |
| 10 | FMR LLC | 3.78M | 3.99% | 189.4K | — | 3.78M | — | HC | Delaware | 2021-08-10 | ↗ |
| 11 | Joseph Edelman | 3.61M | 3.90% | — | 3.61M | — | 3.61M | IN | Delaware | 2020-02-14 | ↗ |
| 12 | Perceptive Advisors LLC | 3.61M | 3.90% | — | 3.61M | — | 3.61M | IA | Delaware | 2020-02-14 | ↗ |
| 13 | Ltd. | 3.41M | 3.70% | — | 3.41M | — | 3.41M | CO | Delaware | 2020-02-14 | ↗ |
| 14 | 95-1411037 | 13.00 | 4.30% | 3.78M | — | 4.05M | — | IA | Delaware | 2021-02-16 | ↗ |
| 15 | BVF Inc. | — | 0.00% | — | — | — | — | CO | Illinois | 2013-02-14 | ↗ |
| 16 | BVF Investments, L.L.C. | — | 0.00% | — | — | — | — | OO | Illinois | 2013-02-14 | ↗ |
| 17 | BVF Partners L.P. | — | 0.00% | — | — | — | — | IA, PN | Illinois | 2013-02-14 | ↗ |
| 18 | Biotechnology Value Fund II, L.P. | — | 0.00% | — | — | — | — | PN | Illinois | 2013-02-14 | ↗ |
| 19 | Biotechnology Value Fund, L.P. | — | 0.00% | — | — | — | — | PN | Illinois | 2013-02-14 | ↗ |
| 20 | Investment 10, L.L.C. | — | 0.00% | — | — | — | — | OO | Illinois | 2013-02-14 | ↗ |
| 21 | Mark N. Lampert | — | 0.00% | — | — | — | — | IN | Illinois | 2013-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
214
-527 vs prev Q
New positions
26
Closed positions
536
Increased
118
Reduced
53
Put/Call ratio
0.00
Calls held
400.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 256.1K +256.1K (+100.0%) | 36.32B +36.3B (+100.0%) | 0.26% +0.257 pp | 0.05% +0.055 pp | USD141.83 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 12.83M +124.4K (+1.0%) | 1.82B +36.1M (+2.0%) | 12.90% +0.061 pp | 0.03% -0.001 pp | USD116.23 +22.0% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 9.70M -6.3K (-0.1%) | 1.38B +13.2M (+1.0%) | 9.75% -0.056 pp | 0.02% -0.001 pp | USD59.99 +136.4% | 84 qtrs — |
| 4 | DODGE & COX | 5.51M -48.6K (-0.9%) | 781.21M +1.2M (+0.1%) | 5.54% -0.077 pp | 0.42% +0.001 pp | USD122.90 +15.4% | 10 qtrs — |
| 5 | JPMORGAN CHASE & CO | 5.20M +470.2K (+9.9%) | 737.57M +73.5M (+11.1%) | 5.23% +0.454 pp | 0.05% +0.007 pp | USD120.02 +18.2% | 45 qtrs — |
| 6 | STATE STREET CORP | 4.24M -103.8K (-2.4%) | 601.74M -8.4M (-1.4%) | 4.26% -0.126 pp | 0.02% -0.001 pp | USD87.83 +61.5% | 51 qtrs — |
| 7 | AQR CAPITAL MANAGEMENT LLC | 3.27M +498.1K (+18.0%) | 462.65M +74.2M (+19.1%) | 3.29% +0.487 pp | 0.24% -0.006 pp | USD132.76 +6.8% | 32 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 2.24M -179.5K (-7.4%) | 317.53M -22.0M (-6.5%) | 2.25% -0.193 pp | 0.49% +0.044 pp | USD117.46 +20.7% | 33 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.06M +34.5K (+1.7%) | 291.34M +7.8M (+2.8%) | 2.07% +0.024 pp | 0.02% 0.000 pp | USD82.07 +72.8% | 78 qtrs — |
| 10 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.87M -994.5K (-34.7%) | 265.54M -136.9M (-34.0%) | 1.88% -1.014 pp | 0.03% -0.014 pp | USD108.03 +31.3% | 75 qtrs — |
| 11 | WELLINGTON MANAGEMENT GROUP LLP | 1.74M -67.2K (-3.7%) | 247.43M -6.9M (-2.7%) | 1.75% -0.077 pp | 0.04% -0.001 pp | USD117.66 +20.5% | 76 qtrs — |
| 12 | BELLEVUE GROUP AG | 1.70M -59.8K (-3.4%) | 241.58M -5.9M (-2.4%) | 1.71% -0.069 pp | 4.58% -0.565 pp | USD85.74 +65.4% | 40 qtrs — |
| 13 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 1.40M +447.9K (+47.2%) | 197.99M +65.0M (+48.8%) | 1.40% +0.445 pp | 0.23% -0.118 pp | USD118.61 +19.6% | 40 qtrs — |
| 14 | LOS ANGELES CAPITAL MANAGEMENT LLC | 1.29M +88.5K (+7.4%) | 178.25M +9.4M (+5.6%) | 1.30% +0.083 pp | 0.61% +0.035 pp | USD131.99 +7.5% | 14 qtrs — |
| 15 | NORTHERN TRUST CORP | 1.22M +295.5K (+31.9%) | 173.20M +43.2M (+33.3%) | 1.23% +0.292 pp | 0.02% +0.006 pp | USD103.62 +36.9% | 51 qtrs — |
| 16 | MORGAN STANLEY | 1.21M -617.6K (-33.8%) | 171.53M -84.9M (-33.1%) | 1.22% -0.630 pp | 0.01% -0.005 pp | USD119.55 +18.6% | 51 qtrs — |
| 17 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1.18M +— (+0.0%) | 167.98M +1.7M (+1.0%) | 1.19% -0.006 pp | 2.15% -0.393 pp | USD107.87 +31.5% | 20 qtrs — |
| 18 | NORGES BANK | 1.15M +1.1M (+100.0%) | 162.66M +162.7M (+100.0%) | 1.15% +1.153 pp | 0.02% +0.017 pp | USD141.83 +0.0% | 1 qtrs NEW |
| 19 | RTW INVESTMENTS, LP | 1.06M +— (+0.0%) | 150.63M +1.5M (+1.0%) | 1.07% -0.005 pp | 1.51% -0.328 pp | USD125.69 +12.8% | 3 qtrs — |
| 20 | TWO SIGMA INVESTMENTS, LP | 984.8K +637.2K (+183.3%) | 139.68M +90.9M (+186.3%) | 0.99% +0.639 pp | 0.20% +0.124 pp | USD141.32 +0.4% | 17 qtrs — |
| 21 | UBS GROUP AG | 983.5K +619.0K (+169.8%) | 139.49M +88.3M (+172.6%) | 0.99% +0.620 pp | 0.02% +0.015 pp | USD133.35 +6.4% | 45 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 850.6K +21.1K (+2.5%) | 120.65M +4.2M (+3.6%) | 0.85% +0.017 pp | 0.02% +0.000 pp | USD85.96 +65.0% | 67 qtrs — |
| 23 | TWO SIGMA ADVISERS, LP | 842.6K +693.8K (+466.4%) | 119.50M +98.6M (+472.2%) | 0.85% +0.697 pp | 0.23% +0.191 pp | USD141.57 +0.2% | 18 qtrs — |
| 24 | ARMISTICE CAPITAL, LLC | 820.2K +123.2K (+17.7%) | 116.33M +18.5M (+18.9%) | 0.82% +0.120 pp | 1.38% -0.067 pp | USD129.33 +9.7% | 16 qtrs — |
| 25 | PICTET ASSET MANAGEMENT HOLDING SA | 776.9K +83.5K (+12.0%) | 110.30M +13.0M (+13.3%) | 0.78% +0.081 pp | 0.11% +0.013 pp | USD122.21 +16.1% | 10 qtrs — |
| 26 | BRAIDWELL LP | 751.5K -128.7K (-14.6%) | 106.59M -17.0M (-13.7%) | 0.76% -0.134 pp | 3.41% -0.258 pp | USD106.29 +33.4% | 12 qtrs — |
| 27 | IEQ CAPITAL, LLC | 745.1K +52.5K (+7.6%) | 105.68M +8.5M (+8.7%) | 0.75% +0.049 pp | 0.32% +0.021 pp | USD110.70 +28.1% | 11 qtrs — |
| 28 | BANK OF NEW YORK MELLON CORP | 738.7K -22.7K (-3.0%) | 104.77M -2.1M (-2.0%) | 0.74% -0.027 pp | 0.02% -0.002 pp | USD82.82 +71.3% | 66 qtrs — |
| 29 | UBS ASSET MANAGEMENT AMERICAS INC | 722.5K -42.8K (-5.6%) | 102.47M -5.0M (-4.6%) | 0.73% -0.047 pp | 0.02% -0.002 pp | USD114.02 +24.4% | 52 qtrs — |
| 30 | DIMENSIONAL FUND ADVISORS LP | 716.5K +6.4K (+0.9%) | 101.61M +1.9M (+1.9%) | 0.72% +0.003 pp | 0.02% 0.000 pp | USD106.75 +32.9% | 44 qtrs — |
| 31 | FIERA CAPITAL CORP | 637.4K +157.7K (+32.9%) | 90.40M +23.1M (+34.3%) | 0.64% +0.156 pp | 0.29% +0.069 pp | USD112.20 +26.4% | 22 qtrs — |
| 32 | RAYMOND JAMES FINANCIAL INC | 631.4K +64.5K (+11.4%) | 89.22M +9.6M (+12.1%) | 0.63% +0.062 pp | 0.03% +0.002 pp | USD137.04 +3.5% | 5 qtrs — |
| 33 | AMERIPRISE FINANCIAL INC | 585.7K -28.9K (-4.7%) | 83.07M -3.2M (-3.7%) | 0.59% -0.032 pp | 0.02% -0.001 pp | USD114.51 +23.9% | 34 qtrs — |
| 34 | SWEDBANK AB | 584.1K +36.8K (+6.7%) | 82.85M +6.0M (+7.8%) | 0.59% +0.034 pp | 0.08% +0.002 pp | USD116.82 +21.4% | 20 qtrs — |
| 35 | GW&K INVESTMENT MANAGEMENT, LLC | 576.6K -17.7K (-3.0%) | 81.79M -1.7M (-2.0%) | 0.58% -0.021 pp | 0.71% -0.031 pp | USD94.18 +50.6% | 40 qtrs — |
| 36 | ALLIANCEBERNSTEIN L.P. | 555.5K -62.6K (-10.1%) | 78.79M -8.0M (-9.2%) | 0.56% -0.066 pp | 0.02% -0.002 pp | USD128.95 +10.0% | 61 qtrs — |
| 37 | FRANKLIN RESOURCES INC | 532.8K -102.2K (-16.1%) | 75.56M -13.6M (-15.2%) | 0.54% -0.106 pp | 0.02% -0.004 pp | USD79.44 +78.5% | 51 qtrs — |
| 38 | BANK OF AMERICA CORP /DE/ | 528.1K -176.2K (-25.0%) | 74.90M -24.0M (-24.2%) | 0.53% -0.181 pp | 0.01% -0.001 pp | USD110.44 +28.4% | 52 qtrs — |
| 39 | PRIMECAP MANAGEMENT CO/CA/ | 507.7K -4.5K (-0.9%) | 72.01M +101.7K (+0.1%) | 0.51% -0.007 pp | 0.05% -0.001 pp | USD108.86 +30.3% | 13 qtrs — |
| 40 | FIRST TRUST ADVISORS LP | 486.8K +123.7K (+34.1%) | 69.04M +18.1M (+35.5%) | 0.49% +0.123 pp | 0.05% +0.012 pp | USD111.88 +26.8% | 40 qtrs — |
| 41 | ZURICH INSURANCE GROUP LTD/FI | 459.4K +459.4K (+100.0%) | 65.16M +65.2M (+100.0%) | 0.46% +0.462 pp | 0.45% +0.452 pp | USD141.83 +0.0% | 3 qtrs — |
| 42 | JANUS HENDERSON GROUP PLC | 459.2K -136.0K (-22.8%) | 65.13M -18.4M (-22.0%) | 0.46% -0.140 pp | 0.03% -0.009 pp | USD71.68 +97.9% | 35 qtrs — |
| 43 | MILLENNIUM MANAGEMENT LLC | 442.9K -534.3K (-54.7%) | 62.81M -74.4M (-54.2%) | 0.45% -0.542 pp | 0.03% -0.032 pp | USD120.36 +17.8% | 34 qtrs — |
| 44 | HOOD RIVER CAPITAL MANAGEMENT LLC | 389.3K -112.2K (-22.4%) | 55.21M -15.2M (-21.6%) | 0.39% -0.115 pp | 0.61% -0.226 pp | USD125.85 +12.7% | 18 qtrs — |
| 45 | DEUTSCHE BANK AG\ | 367.9K -82.9K (-18.4%) | 52.19M -11.1M (-17.5%) | 0.37% -0.085 pp | 0.02% -0.004 pp | USD111.75 +26.9% | 50 qtrs — |
| 46 | GOLDMAN SACHS GROUP INC | 364.5K -245.1K (-40.2%) | 51.70M -33.9M (-39.6%) | 0.37% -0.249 pp | 0.01% -0.004 pp | USD104.07 +36.3% | 73 qtrs — |
| 47 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 360.7K -50.9K (-12.4%) | 51.16M -6.6M (-11.5%) | 0.36% -0.053 pp | 0.03% -0.007 pp | USD133.47 +6.3% | 8 qtrs — |
| 48 | MARSHALL WACE, LLP | 348.8K +251.6K (+258.6%) | 49.48M +35.8M (+262.3%) | 0.35% +0.252 pp | 0.05% +0.031 pp | USD139.67 +1.5% | 5 qtrs — |
| 49 | INVESCO LTD. | 343.4K +19.8K (+6.1%) | 48.71M +3.3M (+7.2%) | 0.35% +0.018 pp | 0.01% +0.000 pp | USD131.00 +8.3% | 57 qtrs — |
| 50 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 339.4K -43.0K (-11.2%) | 47.72M -4.7M (-8.9%) | 0.34% -0.045 pp | 0.08% -0.007 pp | USD125.75 +12.8% | 17 qtrs — |
| 51 | PERCEPTIVE ADVISORS LLC | 331.1K -119.0K (-26.4%) | 46.95M -16.2M (-25.7%) | 0.33% -0.122 pp | 0.84% -0.987 pp | USD132.26 +7.2% | 63 qtrs — |
| 52 | LEGAL & GENERAL GROUP PLC | 330.6K -69.6K (-17.4%) | 46.89M -9.3M (-16.5%) | 0.33% -0.072 pp | 0.01% -0.002 pp | USD104.31 +36.0% | 46 qtrs — |
| 53 | ORBIMED ADVISORS LLC | 314.2K -39.4K (-11.1%) | 44.57M -5.1M (-10.2%) | 0.32% -0.041 pp | 0.91% -0.257 pp | USD124.57 +13.9% | 56 qtrs — |
| 54 | ROYAL BANK OF CANADA | 311.0K +66.3K (+27.1%) | 44.11M +9.8M (+28.4%) | 0.31% +0.065 pp | 0.01% +0.002 pp | USD132.92 +6.7% | 51 qtrs — |
| 55 | CLEARBRIDGE INVESTMENTS, LLC | 310.1K -26.9K (-8.0%) | 43.98M -3.3M (-7.0%) | 0.31% -0.029 pp | 0.04% 0.000 pp | USD99.75 +42.2% | 22 qtrs — |
| 56 | HUDSON BAY CAPITAL MANAGEMENT LP | 305.0K +264.5K (+652.9%) | 43.26M +37.6M (+660.7%) | 0.31% +0.266 pp | 0.14% +0.124 pp | USD137.76 +3.0% | 24 qtrs — |
| 57 | SARISSA CAPITAL MANAGEMENT LP | 303.2K +— (+0.0%) | 43.00M +439.6K (+1.0%) | 0.30% -0.002 pp | 19.29% -4.303 pp | USD112.85 +25.7% | 11 qtrs — |
| 58 | RHUMBLINE ADVISERS | 297.4K -6.1K (-2.0%) | 42.19M -420.3K (-1.0%) | 0.30% -0.008 pp | 0.03% 0.000 pp | USD82.91 +71.1% | 51 qtrs — |
| 59 | CANDRIAM S.C.A. | 293.1K +5.5K (+1.9%) | 41.57M +1.2M (+3.0%) | 0.29% +0.004 pp | 0.21% -0.004 pp | USD108.28 +31.0% | 45 qtrs — |
| 60 | NUVEEN, LLC | 286.8K +41.8K (+17.1%) | 40.67M +6.3M (+18.3%) | 0.29% +0.041 pp | 0.01% +0.002 pp | USD116.83 +21.4% | 4 qtrs — |
| 61 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 281.3K +87.4K (+45.0%) | 39.90M +12.7M (+46.5%) | 0.28% +0.087 pp | 0.07% +0.019 pp | USD135.83 +4.4% | 7 qtrs — |
| 62 | SWISS NATIONAL BANK | 271.8K -13.5K (-4.7%) | 38.55M -1.5M (-3.7%) | 0.27% -0.015 pp | 0.02% 0.000 pp | USD77.45 +83.1% | 51 qtrs — |
| 63 | RENAISSANCE GROUP LLC | 252.3K +665.0 (+0.3%) | 35.78M +459.1K (+1.3%) | 0.25% -0.001 pp | 1.44% +0.104 pp | USD118.04 +20.2% | 6 qtrs — |
| 64 | BARCLAYS PLC | 252.2K +70.7K (+38.9%) | 35.78M +14.9M (+71.0%) | 0.25% +0.070 pp | 0.01% +0.003 pp | USD122.54 +15.7% | 51 qtrs — |
| 65 | ACADIAN ASSET MANAGEMENT LLC | 249.2K +209.7K (+531.2%) | 35.32M +29.8M (+538.3%) | 0.25% +0.211 pp | 0.06% +0.048 pp | USD141.27 +0.4% | 16 qtrs — |
| 66 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 246.3K -34.8K (-12.4%) | 34.93M -4.5M (-11.5%) | 0.25% -0.036 pp | 0.09% -0.033 pp | USD128.57 +10.3% | 17 qtrs — |
| 67 | WELLS FARGO & COMPANY/MN | 242.1K -16.2K (-6.3%) | 34.34M -1.9M (-5.3%) | 0.24% -0.018 pp | 0.01% -0.001 pp | USD115.97 +22.3% | 57 qtrs — |
| 68 | MAN GROUP PLC | 231.2K +150.4K (+186.0%) | 32.79M +21.4M (+189.0%) | 0.23% +0.151 pp | 0.06% +0.036 pp | USD134.88 +5.2% | 17 qtrs — |
| 69 | PRINCIPAL FINANCIAL GROUP INC | 226.4K -5.4K (-2.3%) | 32.11M -427.8K (-1.3%) | 0.23% -0.006 pp | 0.02% +0.000 pp | USD100.54 +41.1% | 62 qtrs — |
| 70 | BROWN ADVISORY INC | 225.3K -243.3K (-51.9%) | 31.95M -33.8M (-51.4%) | 0.23% -0.247 pp | 0.04% -0.041 pp | USD81.86 +73.3% | 42 qtrs — |
| 71 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 222.4K +50.1K (+29.1%) | 31.54M +7.4M (+30.4%) | 0.22% +0.050 pp | 0.00% +0.001 pp | USD130.31 +8.8% | 51 qtrs — |
| 72 | BNP PARIBAS ARBITRAGE, SNC | 214.0K +113.0K (+111.9%) | 30.35M +16.2M (+114.1%) | 0.22% +0.113 pp | 0.01% +0.006 pp | USD130.77 +8.5% | 51 qtrs — |
| 73 | SQUAREPOINT OPS LLC | 209.7K +169.2K (+418.0%) | 29.74M +24.1M (+423.4%) | 0.21% +0.170 pp | 0.03% +0.026 pp | USD138.71 +2.2% | 3 qtrs — |
| 74 | ENVESTNET ASSET MANAGEMENT INC | 206.7K +3.9K (+1.9%) | 29.32M +845.0K (+3.0%) | 0.21% +0.003 pp | 0.01% +0.001 pp | USD116.36 +21.9% | 38 qtrs — |
| 75 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 202.7K -18.6K (-8.4%) | 28.74M -2.3M (-7.5%) | 0.20% -0.020 pp | 0.02% -0.001 pp | USD100.40 +41.3% | 25 qtrs — |
| 76 | HANDELSBANKEN FONDER AB | 200.9K +91.4K (+83.5%) | 28.49M +13.1M (+85.4%) | 0.20% +0.092 pp | 0.09% +0.037 pp | USD125.57 +12.9% | 39 qtrs — |
| 77 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 196.8K +2.7K (+1.4%) | 27.92M +659.4K (+2.4%) | 0.20% +0.002 pp | 0.02% 0.000 pp | USD88.45 +60.4% | 55 qtrs — |
| 78 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 184.0K +— (+0.0%) | 26.10M +266.9K (+1.0%) | 0.19% -0.001 pp | 0.40% -0.007 pp | USD125.69 +12.8% | 3 qtrs — |
| 79 | BRAUN STACEY ASSOCIATES INC | 182.3K -765.0 (-0.4%) | 25.85M +156.9K (+0.6%) | 0.18% -0.002 pp | 0.84% -0.004 pp | USD126.71 +11.9% | 3 qtrs — |
| 80 | SEI INVESTMENTS CO | 179.4K -120.8K (-40.2%) | 25.44M -16.7M (-39.6%) | 0.18% -0.123 pp | 0.03% -0.020 pp | USD123.58 +14.8% | 44 qtrs — |
| 81 | SOLEUS CAPITAL MANAGEMENT, L.P. | 176.0K +38.0K (+27.5%) | 24.96M +5.6M (+28.8%) | 0.18% +0.038 pp | 0.92% -0.055 pp | USD140.69 +0.8% | 2 qtrs — |
| 82 | NEW YORK STATE COMMON RETIREMENT FUND | 174.8K -800.0 (-0.5%) | 24.79M +141.1K (+0.6%) | 0.18% -0.002 pp | 0.03% +0.001 pp | USD79.56 +78.3% | 44 qtrs — |
| 83 | LOOMIS SAYLES & CO L P | 169.2K +8.4K (+5.2%) | 24.00M +1.4M (+6.3%) | 0.17% +0.008 pp | 0.03% +0.002 pp | USD128.26 +10.6% | 3 qtrs — |
| 84 | GOTHAM ASSET MANAGEMENT, LLC | 168.6K +32.2K (+23.6%) | 23.91M +4.8M (+24.9%) | 0.17% +0.032 pp | 0.09% +0.004 pp | USD130.76 +8.5% | 17 qtrs — |
| 85 | ENSIGN PEAK ADVISORS, INC | 167.3K -13.1K (-7.3%) | 23.73M -1.6M (-6.3%) | 0.17% -0.014 pp | 0.04% +0.000 pp | USD128.57 +10.3% | 25 qtrs — |
| 86 | AMUNDI | 166.4K -63.9K (-27.8%) | 23.59M -8.5M (-26.5%) | 0.17% -0.065 pp | 0.01% -0.004 pp | USD114.91 +23.4% | 19 qtrs — |
| 87 | PFM HEALTH SCIENCES, LP | 163.2K +106.0K (+185.1%) | 23.15M +15.1M (+188.0%) | 0.16% +0.106 pp | 2.31% +1.690 pp | USD140.17 +1.2% | 5 qtrs — |
| 88 | EAGLE HEALTH INVESTMENTS LP | 162.8K +— (+0.0%) | 23.09M +236.1K (+1.0%) | 0.16% -0.001 pp | 5.07% -0.926 pp | USD116.28 +22.0% | 6 qtrs — |
| 89 | AMERICAN CENTURY COMPANIES INC | 158.5K +19.6K (+14.1%) | 22.48M +3.0M (+15.3%) | 0.16% +0.019 pp | 0.01% +0.001 pp | USD107.71 +31.7% | 51 qtrs — |
| 90 | BOONE CAPITAL MANAGEMENT LLC | 151.8K -14.6K (-8.8%) | 21.53M -1.8M (-7.8%) | 0.15% -0.016 pp | 6.76% -0.902 pp | USD125.69 +12.8% | 3 qtrs — |
| 91 | JANE STREET GROUP, LLC | 150.0K +89.7K (+148.8%) | 21.27M +12.8M (+151.3%) | 0.15% +0.090 pp | 0.00% +0.002 pp | USD135.92 +4.3% | 6 qtrs — |
| 92 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 150.0K +— (+0.0%) | 21.27M +217.5K (+1.0%) | 0.15% -0.001 pp | 1.06% -0.368 pp | USD136.50 +3.9% | 10 qtrs — |
| 93 | BRIDGEWATER ASSOCIATES, LP | 150.0K +127.0K (+551.1%) | 21.27M +18.0M (+557.8%) | 0.15% +0.128 pp | 0.08% +0.065 pp | USD141.09 +0.5% | 12 qtrs — |
| 94 | BANCO BILBAO VIZCAYA ARGENTARIA, S.A. | 149.2K +1.4K (+0.9%) | 21.15M +406.8K (+2.0%) | 0.15% +0.001 pp | 0.15% -0.011 pp | USD88.17 +60.9% | 17 qtrs — |
| 95 | VIRGINIA RETIREMENT SYSTEMS ET AL | 147.6K +49.2K (+50.0%) | 20.94M +7.1M (+51.5%) | 0.15% +0.049 pp | 0.12% +0.035 pp | USD123.69 +14.7% | 4 qtrs — |
| 96 | DRIEHAUS CAPITAL MANAGEMENT LLC | 145.6K +40.6K (+38.7%) | 20.64M +5.9M (+40.1%) | 0.15% +0.040 pp | 0.14% +0.035 pp | USD140.78 +0.7% | 15 qtrs — |
| 97 | BALYASNY ASSET MANAGEMENT L.P. | 141.1K -62.3K (-30.6%) | 20.01M -8.5M (-29.9%) | 0.14% -0.064 pp | 0.03% -0.011 pp | USD140.38 +1.0% | 5 qtrs — |
| 98 | FREESTONE GROVE PARTNERS LP | 140.5K +8.2K (+6.2%) | 19.93M +1.4M (+7.3%) | 0.14% +0.008 pp | 0.14% +0.005 pp | USD126.19 +12.4% | 4 qtrs — |
| 99 | DNB ASSET MANAGEMENT AS | 139.5K +15.3K (+12.4%) | 19.78M +2.4M (+13.5%) | 0.14% +0.015 pp | 0.07% +0.004 pp | USD114.07 +24.3% | 25 qtrs — |
| 100 | — | 138.8K +— (+0.0%) | 19.69M +201.3K (+1.0%) | 0.14% -0.001 pp | 9.95% -1.604 pp | USD134.63 +5.3% | 5 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.75
Neutral
Ratio by volume
2.59
Bullish
Buys
65
Sells
87
Shares acquired
773.7K
Shares disposed
299.1K
Cash buys
—
Cash sales
2.00
Net activity
+474,557
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-15 | Ratz Andrew | Officer | — | — | Common Stock | 0 | 0.00 | — | 1,018 | D | ↗ |
| 2026-03-04 | ABERNETHY MATT | Officer | G-Gift | D | Common Stock | 2,249 | 0.00 | — | 42,808 | D | ↗ |
| 2026-02-20 | Onyia Jude | Officer | G-Gift | D | Common Stock | 3,110 | 0.00 | — | 25,670 | D | ↗ |
| 2026-02-13 | Onyia Jude | Officer | M-Exempt | D | Restricted Stock Unit | 2,717 | 0.00 | — | 2,717 | D | ↗ |
| 2026-02-13 | Lippoldt Darin | Officer | G-Gift | D | Common Stock | 365 | 0.00 | — | 54,729 | D | ↗ |
| 2026-02-13 | Keswani Sanjay Chandru | Officer | A-Award | A | Restricted Stock Unit | 6,285 | 0.00 | — | 6,285 | D | ↗ |
| 2026-02-13 | Gano Kyle | Director / Officer | M-Exempt | A | Common Stock | 2,566 | 0.00 | — | 147,610 | D | ↗ |
| 2026-02-13 | GORMAN KEVIN CHARLES | Director | M-Exempt | D | Restricted Stock Unit | 5,377 | 0.00 | — | 5,377 | D | ↗ |
| 2026-02-13 | Delaet Ingrid | Officer | M-Exempt | D | Restricted Stock Unit | 1,359 | 0.00 | — | 1,359 | D | ↗ |
| 2026-02-13 | Cooke Julie | Officer | M-Exempt | D | Restricted Stock Unit | 1,401 | 0.00 | — | 2,802 | D | ↗ |
| 2026-02-13 | Boyer David W. | Officer | F-InKind | D | Common Stock | 5,378 | 124.12 | 667.5K | 11,581 | D | ↗ |
| 2026-02-13 | BENEVICH ERIC | Officer | M-Exempt | D | Restricted Stock Unit | 1,961 | 0.00 | — | 3,924 | D | ↗ |
| 2026-02-13 | ABERNETHY MATT | Officer | M-Exempt | D | Restricted Stock Unit | 2,566 | 0.00 | — | 2,566 | D | ↗ |
| 2026-02-12 | Onyia Jude | Officer | M-Exempt | A | Common Stock | 2,560 | 0.00 | — | 18,537 | D | ↗ |
| 2026-02-12 | Lippoldt Darin | Officer | M-Exempt | A | Common Stock | 1,792 | 0.00 | — | 49,584 | D | ↗ |
| 2026-02-12 | Gano Kyle | Director / Officer | M-Exempt | A | Common Stock | 4,907 | 0.00 | — | 146,661 | D | ↗ |
| 2026-02-12 | Delaet Ingrid | Officer | M-Exempt | D | Restricted Stock Unit | 1,600 | 0.00 | — | 4,801 | D | ↗ |
| 2026-02-12 | Cooke Julie | Officer | M-Exempt | D | Restricted Stock Unit | 1,387 | 0.00 | — | 4,161 | D | ↗ |
| 2026-02-12 | Boyer David W. | Officer | F-InKind | D | Common Stock | 864 | 123.10 | 106.4K | 5,449 | D | ↗ |
| 2026-02-12 | BENEVICH ERIC | Officer | F-InKind | D | Common Stock | 1,082 | 123.10 | 133.2K | 53,678 | D | ↗ |
| 2026-02-12 | ABERNETHY MATT | Officer | M-Exempt | D | Restricted Stock Unit | 2,133 | 0.00 | — | 6,401 | D | ↗ |
| 2026-01-31 | Onyia Jude | Officer | M-Exempt | A | Common Stock | 238 | 0.00 | — | 16,119 | D | ↗ |
| 2026-01-31 | Lippoldt Darin | Officer | F-InKind | D | Common Stock | 1,335 | 136.06 | 181.6K | 47,792 | D | ↗ |
| 2026-01-31 | Gano Kyle | Director / Officer | M-Exempt | A | Common Stock | 2,927 | 0.00 | — | 143,334 | D | ↗ |
| 2026-01-31 | GORMAN KEVIN CHARLES | Director | M-Exempt | D | Restricted Stock Unit | 5,142 | 0.00 | — | 0 | D | ↗ |
| 2026-01-31 | Delaet Ingrid | Officer | F-InKind | D | Common Stock | 475 | 136.06 | 64.6K | 5,056 | D | ↗ |
| 2026-01-31 | Cooke Julie | Officer | F-InKind | D | Common Stock | 997 | 136.06 | 135.7K | 27,602 | D | ↗ |
| 2026-01-31 | Boyer David W. | Officer | M-Exempt | A | Common Stock | 2,096 | 0.00 | — | 5,902 | D | ↗ |
| 2026-01-31 | BENEVICH ERIC | Officer | F-InKind | D | Common Stock | 1,292 | 136.06 | 175.8K | 52,755 | D | ↗ |
| 2026-01-31 | ABERNETHY MATT | Officer | M-Exempt | A | Common Stock | 2,437 | 0.00 | — | 38,465 | D | ↗ |
| 2026-01-16 | Gano Kyle | Director / Officer | M-Exempt | A | Common Stock | 34,588 | 35.99 | 1.24M | 174,995 | D | ↗ |
| 2026-01-08 | Lippoldt Darin | Officer | M-Exempt | A | Common Stock | 3,349 | 35.99 | 120.5K | 46,754 | D | ↗ |
| 2025-12-16 | Norwalk Leslie V | Director | S-Sale | D | Common Stock | 1,190 | 155.09 | 184.6K | 6,239 | D | ↗ |
| 2025-12-15 | Norwalk Leslie V | Director | M-Exempt | A | Common Stock | 1,724 | 84.95 | 146.5K | 12,429 | D | ↗ |
| 2025-12-08 | Lippoldt Darin | Officer | M-Exempt | A | Common Stock | 4,376 | 43.24 | 189.2K | 47,781 | D | ↗ |
| 2025-12-03 | LYONS GARY A | Director | M-Exempt | A | Common Stock | 15,000 | 47.89 | 718.4K | 135,482 | D | ↗ |
| 2025-11-29 | Onyia Jude | Officer | M-Exempt | D | Restricted Stock Unit | 4,426 | 0.00 | — | 0 | D | ↗ |
| 2025-11-28 | BENEVICH ERIC | Officer | M-Exempt | D | Incentive Stock Option | 5,970 | 35.99 | 214.9K | 6,860 | D | ↗ |
| 2025-11-25 | MORROW GEORGE J | Director | M-Exempt | A | Common Stock | 15,000 | 47.89 | 718.4K | 22,068 | D | ↗ |
| 2025-11-05 | RASTETTER WILLIAM H | Director | M-Exempt | D | Non-Qualified Stock Option | 18,000 | 47.89 | 862.0K | 0 | D | ↗ |
| 2025-11-04 | Gano Kyle | Director / Officer | S-Sale | D | Common Stock | 300 | 141.97 | 42.6K | 140,407 | D | ↗ |
| 2025-11-01 | Gano Kyle | Director / Officer | M-Exempt | A | Common Stock | 613 | 0.00 | — | 140,720 | D | ↗ |
| 2025-09-03 | Onyia Jude | Officer | G-Gift | D | Common Stock | 1,470 | 0.00 | — | 13,703 | D | ↗ |
| 2025-09-02 | SHERWIN STEPHEN A | Director | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 12,542 | D | ↗ |
| 2025-08-07 | GORMAN KEVIN CHARLES | Director | M-Exempt | D | Non-Qualified Stock Option | 106,322 | 35.99 | 3.83M | 0 | D | ↗ |
| 2025-08-05 | Onyia Jude | Officer | G-Gift | D | Common Stock | 3,116 | 0.00 | — | 15,173 | D | ↗ |
| 2025-07-10 | Delaet Ingrid | Officer | M-Exempt | A | Common Stock | 457 | 79.02 | 36.1K | 5,187 | D | ↗ |
| 2025-07-09 | Onyia Jude | Officer | M-Exempt | A | Common Stock | 59,819 | 84.74 | 5.07M | 78,108 | D | ↗ |
| 2025-07-02 | Onyia Jude | Officer | M-Exempt | D | Non-Qualified Stock Option | 20,362 | 84.74 | 1.73M | 95,087 | D | ↗ |
| 2025-06-02 | Keswani Sanjay Chandru | Officer | A-Award | A | Restricted Stock Unit | 12,846 | 0.00 | — | 12,846 | D | ↗ |
| 2025-05-27 | GORMAN KEVIN CHARLES | Director | S-Sale | D | Common Stock | 9,613 | 120.38 | 1.16M | 514,596 | D | ↗ |
| 2025-05-22 | Sharp Shalini | Director | M-Exempt | D | Restricted Stock Unit | 1,435 | 0.00 | — | 0 | D | ↗ |
| 2025-05-22 | SHERWIN STEPHEN A | Director | M-Exempt | D | Restricted Stock Unit | 2,869 | 0.00 | — | 0 | D | ↗ |
| 2025-05-22 | RASTETTER WILLIAM H | Director | M-Exempt | D | Restricted Stock Unit | 2,869 | 0.00 | — | 0 | D | ↗ |
| 2025-05-22 | POPS RICHARD F | Director | M-Exempt | D | Restricted Stock Unit | 2,869 | 0.00 | — | 0 | D | ↗ |
| 2025-05-22 | POON CHRISTINE A | Director | M-Exempt | D | Restricted Stock Unit | 1,435 | 0.00 | — | 0 | D | ↗ |
| 2025-05-22 | Norwalk Leslie V | Director | M-Exempt | A | Common Stock | 1,435 | 0.00 | — | 2,429 | D | ↗ |
| 2025-05-22 | Mercier Johanna | Director | M-Exempt | A | Common Stock | 1,435 | 0.00 | — | 3,535 | D | ↗ |
| 2025-05-22 | MORROW GEORGE J | Director | M-Exempt | D | Restricted Stock Unit | 2,869 | 0.00 | — | 0 | D | ↗ |
| 2025-05-22 | LYONS GARY A | Director | M-Exempt | D | Restricted Stock Unit | 1,435 | 0.00 | — | 0 | D | ↗ |
| 2025-05-21 | Sharp Shalini | Director | A-Award | A | Restricted Stock Unit | 1,659 | 0.00 | — | 1,659 | D | ↗ |
| 2025-05-21 | SHERWIN STEPHEN A | Director | A-Award | A | Restricted Stock Unit | 3,318 | 0.00 | — | 3,318 | D | ↗ |
| 2025-05-21 | RASTETTER WILLIAM H | Director | A-Award | A | Restricted Stock Unit | 3,318 | 0.00 | — | 3,318 | D | ↗ |
| 2025-05-21 | POPS RICHARD F | Director | A-Award | A | Restricted Stock Unit | 3,318 | 0.00 | — | 3,318 | D | ↗ |
| 2025-05-21 | POON CHRISTINE A | Director | A-Award | A | Restricted Stock Unit | 3,318 | 0.00 | — | 3,318 | D | ↗ |
| 2025-05-21 | Norwalk Leslie V | Director | A-Award | A | Non-Qualified Stock Option | 3,305 | 120.56 | 398.5K | 3,305 | D | ↗ |
| 2025-05-21 | Mercier Johanna | Director | A-Award | A | Restricted Stock Unit | 3,318 | 0.00 | — | 3,318 | D | ↗ |
| 2025-05-21 | MORROW GEORGE J | Director | A-Award | A | Restricted Stock Unit | 3,318 | 0.00 | — | 3,318 | D | ↗ |
| 2025-05-21 | LYONS GARY A | Director | A-Award | A | Non-Qualified Stock Option | 3,305 | 120.56 | 398.5K | 3,305 | D | ↗ |
| 2025-05-21 | GORMAN KEVIN CHARLES | Director | A-Award | A | Non-Qualified Stock Option | 6,610 | 120.56 | 796.9K | 6,610 | D | ↗ |
| 2025-05-16 | Cooke Julie | Officer | M-Exempt | D | Incentive Stock Option | 6,468 | 61.82 | 399.9K | 0 | D | ↗ |
| 2025-05-05 | RASTETTER WILLIAM H | Director | M-Exempt | D | Non-Qualified Stock Option | 30,000 | 42.76 | 1.28M | 0 | D | ↗ |
| 2025-02-14 | ROBERTS EIRY | Officer | S-Sale | D | Common Stock | 500 | 115.04 | 57.5K | 35,640 | D | ↗ |
| 2025-02-13 | SHERWIN STEPHEN A | Director | S-Sale | D | Common Stock | 13,831 | 116.69 | 1.61M | 10,673 | D | ↗ |
| 2025-02-13 | ROBERTS EIRY | Officer | M-Exempt | D | Restricted Stock Unit | 2,113 | 0.00 | — | 4,227 | D | ↗ |
| 2025-02-13 | Onyia Jude | Officer | M-Exempt | D | Restricted Stock Unit | 2,690 | 0.00 | — | 8,070 | D | ↗ |
| 2025-02-13 | Lippoldt Darin | Officer | M-Exempt | D | Restricted Stock Unit | 2,017 | 0.00 | — | 6,053 | D | ↗ |
| 2025-02-13 | Gano Kyle | Director / Officer | S-Sale | D | Common Stock | 1,352 | 116.84 | 158.0K | 138,872 | D | ↗ |
| 2025-02-13 | GORMAN KEVIN CHARLES | Director | M-Exempt | A | Common Stock | 5,603 | 0.00 | — | 527,221 | D | ↗ |
| 2025-02-13 | Delaet Ingrid | Officer | M-Exempt | D | Restricted Stock Unit | 1,401 | 0.00 | — | 4,203 | D | ↗ |
| 2025-02-13 | Cooke Julie | Officer | S-Sale | D | Common Stock | 755 | 116.80 | 88.2K | 20,190 | D | ↗ |
| 2025-02-13 | Boyer David W. | Officer | M-Exempt | D | Restricted Stock Unit | 1,541 | 0.00 | — | 4,624 | D | ↗ |
| 2025-02-13 | BENEVICH ERIC | Officer | M-Exempt | D | Restricted Stock Unit | 2,083 | 0.00 | — | 4,166 | D | ↗ |
| 2025-02-13 | ABERNETHY MATT | Officer | M-Exempt | A | Common Stock | 2,241 | 0.00 | — | 37,016 | D | ↗ |
| 2025-02-12 | ROBERTS EIRY | Officer | A-Award | A | Stock Option | 43,261 | 117.18 | 5.07M | 43,261 | D | ↗ |
| 2025-02-12 | Onyia Jude | Officer | A-Award | A | Restricted Stock Unit | 10,241 | 0.00 | — | 10,241 | D | ↗ |
| 2025-02-12 | Lippoldt Darin | Officer | G-Gift | D | Common Stock | 190 | 0.00 | — | 41,489 | D | ↗ |
| 2025-02-12 | Gano Kyle | Director / Officer | A-Award | A | Stock Option | 104,736 | 117.18 | 12.27M | 104,736 | D | ↗ |
| 2025-02-12 | Delaet Ingrid | Officer | A-Award | A | Stock Option | 34,153 | 117.18 | 4.00M | 34,153 | D | ↗ |
| 2025-02-12 | Cooke Julie | Officer | A-Award | A | Restricted Stock Unit | 5,548 | 0.00 | — | 5,548 | D | ↗ |
| 2025-02-12 | Boyer David W. | Officer | A-Award | A | Restricted Stock Unit | 6,401 | 0.00 | — | 6,401 | D | ↗ |
| 2025-02-12 | BENEVICH ERIC | Officer | A-Award | A | Stock Option | 42,805 | 117.18 | 5.02M | 42,805 | D | ↗ |
| 2025-02-12 | ABERNETHY MATT | Officer | A-Award | A | Stock Option | 45,538 | 117.18 | 5.34M | 45,538 | D | ↗ |
| 2025-02-10 | ROBERTS EIRY | Officer | S-Sale | D | Common Stock | 980 | 118.22 | 115.9K | 33,253 | D | ↗ |
| 2025-02-10 | Lippoldt Darin | Officer | S-Sale | D | Common Stock | 911 | 118.25 | 107.7K | 41,679 | D | ↗ |
| 2025-02-10 | Gano Kyle | Director / Officer | S-Sale | D | Common Stock | 980 | 118.39 | 116.0K | 137,658 | D | ↗ |
| 2025-02-10 | GORMAN KEVIN CHARLES | Director | S-Sale | D | Common Stock | 2,274 | 118.37 | 269.2K | 519,074 | D | ↗ |
| 2025-02-10 | Cooke Julie | Officer | S-Sale | D | Common Stock | 700 | 118.28 | 82.8K | 18,831 | D | ↗ |
| 2025-02-10 | Boyer David W. | Officer | S-Sale | D | Common Stock | 700 | 118.31 | 82.8K | 1,998 | D | ↗ |
| 2025-02-10 | BENEVICH ERIC | Officer | S-Sale | D | Common Stock | 980 | 118.31 | 115.9K | 42,799 | D | ↗ |
| 2025-02-10 | ABERNETHY MATT | Officer | S-Sale | D | Common Stock | 980 | 118.27 | 115.9K | 33,561 | D | ↗ |
| 2025-02-08 | ROBERTS EIRY | Officer | M-Exempt | D | Restricted Stock Unit | 1,860 | 0.00 | — | 0 | D | ↗ |
| 2025-02-08 | Lippoldt Darin | Officer | M-Exempt | D | Restricted Stock Unit | 1,727 | 0.00 | — | 0 | D | ↗ |
| 2025-02-08 | Gano Kyle | Director / Officer | M-Exempt | D | Restricted Stock Unit | 1,860 | 0.00 | — | 0 | D | ↗ |
| 2025-02-08 | GORMAN KEVIN CHARLES | Director | M-Exempt | D | Restricted Stock Unit | 4,318 | 0.00 | — | 0 | D | ↗ |
| 2025-02-08 | Cooke Julie | Officer | M-Exempt | D | Restricted Stock Unit | 1,329 | 0.00 | — | 0 | D | ↗ |
| 2025-02-08 | Boyer David W. | Officer | M-Exempt | D | Restricted Stock Unit | 1,329 | 0.00 | — | 0 | D | ↗ |
| 2025-02-08 | BENEVICH ERIC | Officer | M-Exempt | A | Common Stock | 1,860 | 0.00 | — | 43,779 | D | ↗ |
| 2025-02-08 | ABERNETHY MATT | Officer | M-Exempt | D | Restricted Stock Unit | 1,860 | 0.00 | — | 0 | D | ↗ |
| 2025-02-03 | Delaet Ingrid | Officer | M-Exempt | A | Common Stock | 1,179 | 0.00 | — | 4,065 | D | ↗ |
| 2025-01-31 | ROBERTS EIRY | Officer | M-Exempt | A | Common Stock | 2,769 | 0.00 | — | 33,830 | D | ↗ |
| 2025-01-31 | Onyia Jude | Officer | M-Exempt | A | Common Stock | 238 | 0.00 | — | 15,687 | D | ↗ |
| 2025-01-31 | Lippoldt Darin | Officer | M-Exempt | D | Restricted Stock Unit | 2,373 | 0.00 | — | 2,373 | D | ↗ |
| 2025-01-31 | Gano Kyle | Director / Officer | M-Exempt | D | Restricted Stock Unit | 2,927 | 0.00 | — | 2,927 | D | ↗ |
| 2025-01-31 | GORMAN KEVIN CHARLES | Director | M-Exempt | D | Restricted Stock Unit | 5,141 | 0.00 | — | 5,142 | D | ↗ |
| 2025-01-31 | Delaet Ingrid | Officer | M-Exempt | A | Common Stock | 801 | 0.00 | — | 3,308 | D | ↗ |
| 2025-01-31 | Cooke Julie | Officer | M-Exempt | A | Common Stock | 1,740 | 0.00 | — | 19,942 | D | ↗ |
| 2025-01-31 | Boyer David W. | Officer | M-Exempt | A | Common Stock | 2,096 | 0.00 | — | 2,473 | D | ↗ |
| 2025-01-31 | BENEVICH ERIC | Officer | M-Exempt | A | Common Stock | 2,294 | 0.00 | — | 43,126 | D | ↗ |
| 2025-01-31 | ABERNETHY MATT | Officer | M-Exempt | A | Common Stock | 2,436 | 0.00 | — | 33,964 | D | ↗ |
| 2025-01-27 | GORMAN KEVIN CHARLES | Director | M-Exempt | A | Common Stock | 146,105 | 32.99 | 4.82M | 660,701 | D | ↗ |
| 2025-01-15 | Gano Kyle | Director / Officer | S-Sale | D | Common Stock | 60,188 | 141.50 | 8.52M | 135,392 | D | ↗ |
| 2024-12-31 | Delaet Ingrid | Officer | M-Exempt | A | Common Stock | 272 | 79.02 | 21.5K | 2,779 | D | ↗ |
| 2024-12-17 | ROBERTS EIRY | Officer | A-Award | A | Stock Option | 27,770 | 136.69 | 3.80M | 27,770 | D | ↗ |
| 2024-12-17 | Delaet Ingrid | Officer | S-Sale | D | Common Stock | 1,091 | 135.00 | 147.3K | 2,507 | D | ↗ |
| 2024-11-29 | Onyia Jude | Officer | S-Sale | D | Common Stock | 2,331 | 126.29 | 294.4K | 15,449 | D | ↗ |
| 2024-11-08 | ROBERTS EIRY | Officer | M-Exempt | D | Incentive Stock Option | 1,233 | 81.05 | 99.9K | 0 | D | ↗ |
| 2024-11-04 | SHERWIN STEPHEN A | Director | G-Gift | D | Common Stock | 2,000 | 0.00 | — | 24,504 | D | ↗ |
| 2024-11-01 | Gano Kyle | Director / Officer | A-Award | A | Stock Option | 13,344 | 122.21 | 1.63M | 13,344 | D | ↗ |
| 2024-10-03 | Boyer David W. | Officer | S-Sale | D | Common Stock | 1,295 | 113.66 | 147.2K | 377 | D | ↗ |
| 2024-09-13 | Boyer David W. | Officer | S-Sale | D | Common Stock | 3,461 | 121.88 | 421.8K | 1,672 | — | ↗ |
| 2024-08-15 | RASTETTER WILLIAM H | Director | S-Sale | D | Common Stock | 14,250 | 146.69 | 2.09M | 37,491 | — | ↗ |
| 2024-08-13 | LYONS GARY A | Director | M-Exempt | A | Common Stock | 11,570 | 42.76 | 494.7K | 130,617 | — | ↗ |
| 2024-08-13 | Delaet Ingrid | Officer | M-Exempt | D | Non-Qualified Stock Option | 3,043 | 103.52 | 315.0K | 22,049 | — | ↗ |
| 2024-08-13 | ABERNETHY MATT | Officer | M-Exempt | D | Non-Qualified Stock Option | 14,100 | 73.60 | 1.04M | 0 | — | ↗ |
| 2024-08-06 | Delaet Ingrid | Officer | S-Sale | D | Common Stock | 273 | 147.70 | 40.3K | 6,607 | — | ↗ |
| 2024-08-01 | Lippoldt Darin | Officer | M-Exempt | A | Common Stock | 2,996 | 79.02 | 236.7K | 42,736 | — | ↗ |
| 2024-08-01 | Cooke Julie | Officer | M-Exempt | D | Non-Qualified Stock Option | 12,632 | 61.82 | 780.9K | 0 | — | ↗ |
| 2024-07-16 | Lippoldt Darin | Officer | S-Sale | D | Common Stock | 7,004 | 150.00 | 1.05M | 39,740 | — | ↗ |
| 2024-07-16 | LYONS GARY A | Director | M-Exempt | D | Non-Qualified Stock Option | 930 | 42.76 | 39.8K | 11,570 | — | ↗ |
| 2024-07-16 | Delaet Ingrid | Officer | S-Sale | D | Common Stock | 900 | 150.04 | 135.0K | 6,607 | — | ↗ |
| 2024-07-16 | Cooke Julie | Officer | S-Sale | D | Common Stock | 900 | 150.04 | 135.0K | 18,202 | — | ↗ |
| 2024-07-16 | ABERNETHY MATT | Officer | M-Exempt | D | Non-Qualified Stock Option | 900 | 73.60 | 66.2K | 14,100 | — | ↗ |
| 2024-07-01 | Delaet Ingrid | Officer | S-Sale | D | Common Stock | 272 | 138.11 | 37.6K | 7,507 | — | ↗ |
| 2024-07-01 | Cooke Julie | Officer | M-Exempt | D | Non-Qualified Stock Option | 10,000 | 61.82 | 618.2K | 13,532 | — | ↗ |
| 2024-05-31 | Delaet Ingrid | Officer | M-Exempt | D | Non-Qualified Stock Option | 273 | 79.02 | 21.6K | 4,626 | — | ↗ |
| 2024-05-29 | SHERWIN STEPHEN A | Director | M-Exempt | A | Common Stock | 25,000 | 42.76 | 1.07M | 51,504 | — | ↗ |
| 2024-05-22 | Sharp Shalini | Director | A-Award | A | Restricted Stock Unit | 1,435 | 0.00 | — | 1,435 | — | ↗ |
| 2024-05-22 | SHERWIN STEPHEN A | Director | A-Award | A | Restricted Stock Unit | 2,869 | 0.00 | — | 2,869 | — | ↗ |
| 2024-05-22 | RASTETTER WILLIAM H | Director | A-Award | A | Restricted Stock Unit | 2,869 | 0.00 | — | 2,869 | — | ↗ |
| 2024-05-22 | POPS RICHARD F | Director | A-Award | A | Restricted Stock Unit | 2,869 | 0.00 | — | 2,869 | — | ↗ |
| 2024-05-22 | POON CHRISTINE A | Director | A-Award | A | Restricted Stock Unit | 1,435 | 0.00 | — | 1,435 | — | ↗ |
| 2024-05-22 | Norwalk Leslie V | Director | A-Award | A | Restricted Stock Unit | 1,435 | 0.00 | — | 1,435 | — | ↗ |
| 2024-05-22 | Mercier Johanna | Director | A-Award | A | Non-Qualified Stock Option | 2,982 | 139.43 | 415.8K | 2,982 | — | ↗ |
| 2024-05-22 | MORROW GEORGE J | Director | A-Award | A | Restricted Stock Unit | 2,869 | 0.00 | — | 2,869 | — | ↗ |
| 2024-05-22 | LYONS GARY A | Director | A-Award | A | Restricted Stock Unit | 1,435 | 0.00 | — | 1,435 | — | ↗ |
| 2024-05-17 | Sharp Shalini | Director | S-Sale | D | Common Stock | 1,106 | 141.90 | 156.9K | 994 | — | ↗ |
| 2024-05-17 | SHERWIN STEPHEN A | Director | M-Exempt | D | Restricted Stock Unit | 4,199 | 0.00 | — | 0 | — | ↗ |
| 2024-05-17 | POPS RICHARD F | Director | M-Exempt | D | Restricted Stock Unit | 4,199 | 0.00 | — | 0 | — | ↗ |
| 2024-05-17 | Norwalk Leslie V | Director | M-Exempt | A | Common Stock | 2,100 | 0.00 | — | 2,100 | — | ↗ |
| 2024-05-17 | Mercier Johanna | Director | M-Exempt | D | Restricted Stock Unit | 2,100 | 0.00 | — | 0 | — | ↗ |
| 2024-05-17 | MORROW GEORGE J | Director | M-Exempt | D | Restricted Stock Unit | 4,199 | 0.00 | — | 0 | — | ↗ |
| 2024-05-17 | LYONS GARY A | Director | M-Exempt | D | Restricted Stock Unit | 2,100 | 0.00 | — | 0 | — | ↗ |
| 2024-05-15 | ABERNETHY MATT | Officer | M-Exempt | A | Common Stock | 15,000 | 73.60 | 1.10M | 46,528 | — | ↗ |
| 2024-05-14 | LYONS GARY A | Director | M-Exempt | D | Non-Qualified Stock Option | 12,500 | 42.76 | 534.5K | 12,500 | — | ↗ |
| 2024-05-14 | ABERNETHY MATT | Officer | S-Sale | D | Common Stock | 15,000 | 135.66 | 2.03M | 31,528 | — | ↗ |
| 2024-05-06 | Delaet Ingrid | Officer | M-Exempt | D | Non-Qualified Stock Option | 273 | 79.02 | 21.6K | 4,899 | — | ↗ |
| 2024-04-15 | BENEVICH ERIC | Officer | M-Exempt | A | Common Stock | 12,587 | 81.05 | 1.02M | 53,365 | — | ↗ |
| 2024-04-01 | Delaet Ingrid | Officer | M-Exempt | D | Non-Qualified Stock Option | 272 | 79.02 | 21.5K | 5,172 | — | ↗ |
| 2024-03-21 | Delaet Ingrid | Officer | M-Exempt | D | Non-Qualified Stock Option | 5,000 | 103.52 | 517.6K | 27,049 | — | ↗ |
| 2024-03-14 | MORROW GEORGE J | Director | S-Sale | D | Common Stock | 20,000 | 139.42 | 2.79M | 0 | — | ↗ |
| 2024-03-14 | BENEVICH ERIC | Officer | M-Exempt | D | Non-Qualified Stock Option | 69,521 | 81.05 | 5.63M | 12,587 | — | ↗ |
| 2024-03-13 | POPS RICHARD F | Director | M-Exempt | A | Common Stock | 23,200 | 42.76 | 992.0K | 52,712 | — | ↗ |
| 2024-03-13 | Delaet Ingrid | Officer | M-Exempt | A | Common Stock | 3,000 | 106.02 | 318.1K | 10,507 | — | ↗ |
| 2024-03-11 | POPS RICHARD F | Director | M-Exempt | D | Non-Qualified Stock Option | 100 | 42.76 | 4.3K | 23,200 | — | ↗ |
| 2024-03-11 | Delaet Ingrid | Officer | M-Exempt | D | Non-Qualified Stock Option | 200 | 106.02 | 21.2K | 7,367 | — | ↗ |
| 2024-03-08 | POPS RICHARD F | Director | M-Exempt | D | Non-Qualified Stock Option | 1,700 | 42.76 | 72.7K | 23,300 | — | ↗ |
| 2024-03-08 | Delaet Ingrid | Officer | M-Exempt | A | Common Stock | 1,800 | 106.02 | 190.8K | 9,307 | — | ↗ |
| 2024-02-29 | Delaet Ingrid | Officer | M-Exempt | A | Common Stock | 273 | 79.02 | 21.6K | 7,780 | — | ↗ |
| 2024-02-28 | Delaet Ingrid | Officer | M-Exempt | D | Non-Qualified Stock Option | 1,544 | 79.02 | 122.0K | 5,717 | — | ↗ |
| 2024-02-28 | BENEVICH ERIC | Officer | M-Exempt | A | Common Stock | 21,857 | 79.02 | 1.73M | 62,473 | — | ↗ |
| 2024-02-27 | Norwalk Leslie V | Director | M-Exempt | A | Common Stock | 8,000 | 84.95 | 679.6K | 8,000 | — | ↗ |
| 2024-02-20 | POPS RICHARD F | Director | S-Sale | D | Common Stock | 15,000 | 132.47 | 1.99M | 29,512 | — | ↗ |
| 2024-02-13 | ROBERTS EIRY | Officer | A-Award | A | Restricted Stock Unit | 4,483 | 0.00 | — | 4,483 | — | ↗ |
| 2024-02-13 | Onyia Jude | Officer | A-Award | A | Stock Option | 54,069 | 133.84 | 7.24M | 54,069 | — | ↗ |
| 2024-02-13 | Lippoldt Darin | Officer | A-Award | A | Restricted Stock Unit | 8,070 | 0.00 | — | 8,070 | — | ↗ |
| 2024-02-13 | Gano Kyle | Officer | S-Sale | D | Common Stock | 1,352 | 132.89 | 179.7K | 135,166 | — | ↗ |
| 2024-02-13 | GORMAN KEVIN CHARLES | Director / Officer | M-Exempt | D | Incentive Stock Option | 2,312 | 43.24 | 100.0K | 0 | — | ↗ |
| 2024-02-13 | Delaet Ingrid | Officer | A-Award | A | Restricted Stock Unit | 5,604 | 0.00 | — | 5,604 | — | ↗ |
| 2024-02-13 | Cooke Julie | Officer | A-Award | A | Restricted Stock Unit | 5,604 | 0.00 | — | 5,604 | — | ↗ |
| 2024-02-13 | Boyer David W. | Officer | A-Award | A | Stock Option | 30,977 | 133.84 | 4.15M | 30,977 | — | ↗ |
| 2024-02-13 | BENEVICH ERIC | Officer | A-Award | A | Restricted Stock Unit | 7,846 | 0.00 | — | 7,846 | — | ↗ |
| 2024-02-13 | ABERNETHY MATT | Officer | A-Award | A | Stock Option | 45,058 | 133.84 | 6.03M | 45,058 | — | ↗ |
| 2024-02-08 | ROBERTS EIRY | Officer | S-Sale | D | Common Stock | 980 | 134.21 | 131.5K | 22,717 | — | ↗ |
| 2024-02-08 | Lippoldt Darin | Officer | S-Sale | D | Common Stock | 911 | 134.24 | 122.3K | 38,755 | — | ↗ |
| 2024-02-08 | Gano Kyle | Officer | S-Sale | D | Common Stock | 980 | 134.20 | 131.5K | 133,952 | — | ↗ |
| 2024-02-08 | GORMAN KEVIN CHARLES | Director / Officer | S-Sale | D | Common Stock | 2,274 | 134.15 | 305.1K | 506,962 | — | ↗ |
| 2024-02-08 | Cooke Julie | Officer | S-Sale | D | Common Stock | 629 | 136.78 | 86.0K | 17,263 | — | ↗ |
| 2024-02-08 | Boyer David W. | Officer | S-Sale | D | Common Stock | 628 | 136.78 | 85.9K | 4,895 | — | ↗ |
| 2024-02-08 | BENEVICH ERIC | Officer | S-Sale | D | Common Stock | 980 | 134.19 | 131.5K | 39,631 | — | ↗ |
Executive team
Top executives
EBIT / Employee
353.6K
Shares Outstanding
100.36M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Matthew C. Abernethy Chief Financial Officer | 920.0K | 966.0K | 5.75M | 5.75M | — | 62.9K | 13.45M | 85.51% | ↗ |
| 2 | 2025 | Sanjay Keswani, M.D. Chief Medical Officer Jude Onyia, Ph.D. Chief Scientific Officer | 379.2K | 488.0K | 4.00M | 4.00M | — | 140.6K | 9.01M | 88.81% | ↗ |
| 3 | 2025 | Eiry W. Roberts, M.D. | 720.5K | 645.0K | 3.00M | 3.00M | — | 45.3K | 7.41M | 80.96% | ↗ |
| 4 | 2025 | Eric Benevich Chief Commercial Officer | 668.7K | 463.0K | 2.35M | 2.35M | — | 57.3K | 5.89M | 79.81% | ↗ |
| 5 | 2024 | Kyle W. Gano, Ph.D. Chief Executive Officer | 698.2K | 536.9K | 3.70M | 3.55M | — | 50.2K | 8.54M | 84.94% | ↗ |
| 6 | 2024 | Kevin C. Gorman, Ph.D. Former Chief Executive Officer | 698.2K | 536.9K | 3.70M | 3.55M | — | 50.2K | 8.54M | 84.94% | ↗ |
| 7 | 2024 | Sanjay Keswani, M.D. Chief Medical Officer Jude Onyia, Ph.D. Chief Scientific Officer | 676.5K | 505.7K | 2.44M | 3.36M | — | 53.6K | 7.04M | 82.44% | ↗ |
| 8 | 2024 | Eric Benevich Eiry W. Roberts, M.D. Chief Medical Officer | 676.5K | 505.7K | 2.44M | 3.36M | — | 53.6K | 7.04M | 82.44% | ↗ |
| 9 | 2024 | Strategic Advisor | 686.8K | 513.4K | 2.35M | 3.15M | — | 64.1K | 6.76M | 81.31% | ↗ |
| 10 | 2024 | Matthew C. Abernethy Chief Financial Officer | 684.8K | 452.8K | 2.60M | 2.80M | — | 57.6K | 6.60M | 81.88% | ↗ |
| 11 | 2024 | Eric Benevich Chief Commercial Officer | 636.8K | 366.2K | 2.80M | 2.45M | — | 53.1K | 6.31M | 83.25% | ↗ |
| 12 | 2023 | Kevin C. Gorman, Ph.D. Former Chief Executive Officer | 946.0K | 1.04M | 7.02M | 6.68M | — | 64.0K | 15.75M | 86.98% | ↗ |
| 13 | 2023 | Eiry W. Roberts, M.D. Chief Medical Officer | 638.3K | 351.0K | 2.63M | 3.38M | — | 233.8K | 7.22M | 83.07% | ↗ |
| 14 | 2023 | Sanjay Keswani, M.D. Chief Medical Officer Jude Onyia, Ph.D. Chief Scientific Officer | 638.3K | 526.0K | 2.63M | 3.38M | — | 58.8K | 7.22M | 83.07% | ↗ |
| 15 | 2023 | Kevin C. Gorman, Ph.D. Chief Executive Officer Matthew C. Abernethy Chief Financial Officer Kyle W. Gano, Ph.D. Chief Business Development and Strategy Officer Jude Onyia, Ph.D. Chief Scientific Officer | 646.1K | 355.3K | 1.81M | 3.19M | — | 56.4K | 6.06M | 82.54% | ↗ |
| 16 | 2023 | Matthew C. Abernethy Chief Financial Officer | 646.1K | 355.3K | 1.81M | 3.19M | — | 56.4K | 6.06M | 82.54% | ↗ |
| 17 | 2023 | Kyle W. Gano, Ph.D. Chief Executive Officer | 602.9K | 331.6K | 1.81M | 3.19M | — | 55.6K | 5.99M | 83.47% | ↗ |
| 18 | 2023 | Eric Benevich Eiry W. Roberts, M.D. Chief Medical Officer | 660.3K | 399.5K | 2.13M | 2.63M | — | 63.9K | 5.87M | 80.87% | ↗ |
| 19 | 2023 | Eiry W. Roberts, M.D. | 660.3K | 399.5K | 2.13M | 2.63M | — | 63.9K | 5.87M | 80.87% | ↗ |
| 20 | 2022 | Kevin C. Gorman, Ph.D. Former Chief Executive Officer | 860.0K | 989.0K | 5.13M | 4.88M | — | 53.3K | 11.90M | 84.02% | ↗ |
| 21 | 2022 | Kevin C. Gorman, Ph.D. Chief Executive Officer Matthew C. Abernethy Chief Financial Officer Kyle W. Gano, Ph.D. Chief Business Development and Strategy Officer Darin M. Lippoldt Chief Legal Officer | 860.0K | 989.0K | 5.13M | 4.88M | — | 53.3K | 11.90M | 84.02% | ↗ |
| 22 | 2022 | Eric Benevich Eiry W. Roberts, M.D. Chief Medical Officer | 631.9K | 345.2K | 2.08M | 2.63M | — | 58.0K | 5.74M | 81.95% | ↗ |
| 23 | 2022 | Eiry W. Roberts, M.D. Chief Medical Officer | 631.9K | 345.2K | 2.08M | 2.63M | — | 58.0K | 5.74M | 81.95% | ↗ |
| 24 | 2022 | Kyle W. Gano, Ph.D. Chief Executive Officer | 550.6K | 332.4K | 1.73M | 2.78M | — | 38.5K | 5.42M | 83.00% | ↗ |
| 25 | 2022 | Matthew C. Abernethy Chief Financial Officer | 618.2K | 373.3K | 1.57M | 2.31M | — | 52.6K | 4.92M | 78.80% | ↗ |
| 26 | 2022 | Kevin C. Gorman, Ph.D. Chief Executive Officer Matthew C. Abernethy Chief Financial Officer Kyle W. Gano, Ph.D. Chief Business Development and Strategy Officer Jude Onyia, Ph.D. Chief Scientific Officer | 618.2K | 373.3K | 1.57M | 2.31M | — | 52.6K | 4.92M | 78.80% | ↗ |
| 27 | 2021 | Matthew C. Abernethy Chief Financial Officer | 825.0K | 701.3K | 6.41M | 6.09M | — | 55.0K | 14.08M | 88.77% | ↗ |
| 28 | 2021 | Kevin C. Gorman, Ph.D. Chief Executive Officer Matthew C. Abernethy Chief Financial Officer Kyle W. Gano, Ph.D. Chief Business Development and Strategy Officer Jude Onyia, Ph.D. Chief Scientific Officer | 825.0K | 701.3K | 6.41M | 6.09M | — | 55.0K | 14.08M | 88.77% | ↗ |
| 29 | 2021 | Jude Onyia, Ph.D. Chief Scientific Officer Eiry W. Roberts, M.D. Chief Medical Officer | 52.3K | 26.2K | 3.00M | 4.50M | — | 2.9K | 7.58M | 98.93% | ↗ |
| 30 | 2021 | Eiry W. Roberts, M.D. Chief Medical Officer | 604.7K | 272.1K | 2.88M | 2.63M | — | 48.6K | 6.43M | 85.60% | ↗ |
| 31 | 2021 | Eric Benevich Chief Commercial Officer | 588.8K | 265.0K | 2.38M | 2.63M | — | 53.0K | 5.91M | 84.65% | ↗ |
| 32 | 2021 | Kevin C. Gorman, Ph.D. Chief Executive Officer Matthew C. Abernethy Chief Financial Officer Kyle W. Gano, Ph.D. Chief Business Development and Strategy Officer Darin M. Lippoldt Chief Legal Officer | 517.0K | 271.4K | 2.38M | 2.63M | — | 22.8K | 5.81M | 86.04% | ↗ |
| 33 | 2020 | Kevin C. Gorman, Ph.D. Chief Executive Officer | 775.0K | 542.5K | 5.38M | 7.12M | — | 63.3K | 13.88M | 90.05% | ↗ |
| 34 | 2020 | Kyle W. Gano, Ph.D. Chief Development and Strategy Officer Eiry W. Roberts, M.D. Chief Medical Officer | 499.9K | 200.0K | 3.00M | 3.00M | — | 49.0K | 6.75M | 88.90% | ↗ |
| 35 | 2020 | Eric Benevich Chief Commercial Officer | 499.9K | 200.0K | 3.00M | 3.00M | — | 49.0K | 6.75M | 88.90% | ↗ |
| 36 | 2020 | Kevin C. Gorman, Ph.D. Chief Executive Officer Matthew C. Abernethy Chief Financial Officer Kyle W. Gano, Ph.D. Chief Business Development and Strategy Officer Darin M. Lippoldt Chief Legal Officer | 545.2K | 190.8K | 2.50M | 3.00M | — | 45.0K | 6.28M | 87.57% | ↗ |
| 37 | 2020 | Matthew C. Abernethy Chief Financial Officer | 545.2K | 190.8K | 2.50M | 3.00M | — | 45.0K | 6.28M | 87.57% | ↗ |
| 38 | 2020 | Jude Onyia, Ph.D. Chief Scientific Officer Eiry W. Roberts, M.D. Chief Medical Officer | 575.9K | 216.0K | 2.38M | 2.62M | — | 56.1K | 5.85M | 85.50% | ↗ |
| 39 | 2020 | Eiry W. Roberts, M.D. Chief Medical Officer | 575.9K | 216.0K | 2.38M | 2.62M | — | 56.1K | 5.85M | 85.50% | ↗ |
| 40 | 2019 | Kevin C. Gorman, Ph.D. Chief Executive Officer | 725.0K | 667.0K | 2.00M | 6.00M | — | 58.2K | 9.45M | 84.65% | ↗ |
| 41 | 2019 | Matthew C. Abernethy Chief Financial Officer | 495.6K | 285.0K | 1.25M | 3.75M | — | 42.2K | 5.82M | 85.87% | ↗ |
| 42 | 2019 | Eric Benevich Chief Commercial Officer | 467.2K | 280.3K | 1.25M | 3.75M | — | 45.5K | 5.79M | 86.31% | ↗ |
| 43 | 2019 | Eric Benevich Chief Commercial Officer Haig P. Bozigian, Ph.D. Chief Development Officer | 467.2K | 280.3K | 1.25M | 3.75M | — | 45.5K | 5.79M | 86.31% | ↗ |
| 44 | 2019 | Jude Onyia, Ph.D. Chief Scientific Officer Eiry W. Roberts, M.D. Chief Medical Officer | 538.2K | 309.5K | 1.00M | 3.00M | — | 51.9K | 4.90M | 81.64% | ↗ |
| 45 | 2019 | Eiry W. Roberts, M.D. Chief Medical Officer | 461.5K | 265.4K | 1.00M | 3.00M | — | 53.8K | 4.78M | 83.67% | ↗ |
| 46 | 2019 | Kyle W. Gano, Ph.D. Chief Development and Strategy Officer Eiry W. Roberts, M.D. Chief Medical Officer | 443.4K | 266.0K | 1.00M | 3.00M | — | 16.2K | 4.73M | 84.65% | ↗ |
| 47 | 2018 | Kevin C. Gorman, Ph.D. Chief Executive Officer | 675.0K | 425.3K | 3.00M | 4.49M | — | 47.0K | 8.63M | 86.71% | ↗ |
| 48 | 2018 | Eiry W. Roberts, M.D. Chief Medical Officer | 490.7K | 220.8K | 4.05M | 2.86M | — | 671.6K | 8.30M | 83.34% | ↗ |
| 49 | 2018 | Kyle W. Gano, Ph.D. Chief Development and Strategy Officer Eiry W. Roberts, M.D. Chief Medical Officer | 403.1K | 191.5K | 2.66M | 1.31M | — | 8.1K | 4.57M | 86.81% | ↗ |
| 50 | 2018 | Matthew C. Abernethy Chief Financial Officer Eric Benevich Chief Commercial Officer Kyle W. Gano, Ph.D. Chief Business Development Officer | 432.6K | 205.5K | 1.50M | 1.50M | — | 38.8K | 3.67M | 81.57% | ↗ |
| 51 | 2018 | Eric Benevich Chief Commercial Officer | 432.6K | 205.5K | 1.50M | 1.50M | — | 38.8K | 3.67M | 81.57% | ↗ |
| 52 | 2018 | Eric Benevich Chief Commercial Officer Haig P. Bozigian, Ph.D. Chief Development Officer | 432.6K | 205.5K | 1.50M | 1.50M | — | 38.8K | 3.67M | 81.57% | ↗ |
| 53 | 2018 | Matthew C. Abernethy Chief Financial Officer | 420.0K | 199.5K | 2.00M | — | — | 69.7K | 2.69M | 74.34% | ↗ |
| 54 | 2017 | David-Alexandrè C. Gros, M.D. Former President, Chief Operating Officer and interim Chief Financial Officer | 513.2K | — | 1.08M | 8.20M | — | 1.56M | 11.36M | 81.72% | ↗ |
| 55 | 2017 | Kevin C. Gorman, Ph.D. Chief Executive Officer | 640.0K | 515.2K | 1.43M | 4.93M | — | 44.4K | 7.56M | 84.13% | ↗ |
| 56 | 2017 | Matthew C. Abernethy Chief Financial Officer Eric Benevich Chief Commercial Officer Kyle W. Gano, Ph.D. Chief Business Development Officer | 38.2K | 20.1K | 920.0K | 2.42M | — | 394.2K | 3.79M | 88.06% | ↗ |
| 57 | 2017 | Matthew C. Abernethy Chief Financial Officer | 38.2K | 20.1K | 920.0K | 2.42M | — | 394.2K | 3.79M | 88.06% | ↗ |
| 58 | 2017 | Timothy P. Coughlin Former Chief Financial Officer Christopher F. O’Brien, M.D. Former Chief Medical Officer Haig P. Bozigian, Ph.D. Chief Development Officer | 501.6K | 288.4K | 458.3K | 1.83M | — | 29.3K | 3.10M | 73.60% | ↗ |
| 59 | 2017 | Eric Benevich Chief Commercial Officer Haig P. Bozigian, Ph.D. Chief Development Officer | 410.0K | 246.0K | 458.3K | 1.83M | — | 37.7K | 2.98M | 76.70% | ↗ |
| 60 | 2017 | Eric Benevich Chief Commercial Officer | 408.8K | 235.1K | 458.3K | 1.83M | — | 41.7K | 2.97M | 76.91% | ↗ |
| 61 | 2016 | Kevin C. Gorman, Ph.D. Chief Executive Officer | 592.0K | 337.4K | 2.11M | 2.20M | — | 43.1K | 5.29M | 81.61% | ↗ |
| 62 | 2016 | Timothy P. Coughlin Former Chief Financial Officer Christopher F. O’Brien, M.D. Former Chief Medical Officer Haig P. Bozigian, Ph.D. Chief Development Officer | 487.0K | 243.5K | 1.56M | 1.22M | — | 28.2K | 3.54M | 78.57% | ↗ |
| 63 | 2016 | Eric Benevich Chief Commercial Officer | 376.0K | 169.2K | 1.05M | 831.8K | — | 62.7K | 2.49M | 75.59% | ↗ |
| 64 | 2016 | Matthew C. Abernethy Chief Financial Officer Eric Benevich Chief Commercial Officer Kyle W. Gano, Ph.D. Chief Business Development Officer | 376.0K | 169.2K | 1.05M | 831.8K | — | 62.7K | 2.49M | 75.59% | ↗ |
| 65 | 2016 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer Timothy P. Coughlin Chief Financial Officer Christopher F. O’Brien, M.D. Chief Medical Officer Eric Benevich Chief Commercial Officer Haig P. Bozigian, Ph.D. Chief Development Officer | 376.0K | 169.2K | 1.05M | 831.8K | — | 62.7K | 2.49M | 75.59% | ↗ |
| 66 | 2015 | Kevin C. Gorman, Ph.D. Chief Executive Officer | 575.0K | 345.0K | 824.8K | 3.23M | — | 42.2K | 5.01M | 80.80% | ↗ |
| 67 | 2015 | Eric Benevich Chief Commercial Officer | 218.5K | 109.3K | 1.04M | 1.65M | — | 222.0K | 3.24M | 83.04% | ↗ |
| 68 | 2015 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer Timothy P. Coughlin Chief Financial Officer Christopher F. O’Brien, M.D. Chief Medical Officer Eric Benevich Chief Commercial Officer | 472.8K | 236.4K | 395.9K | 1.61M | — | 27.1K | 2.74M | 73.17% | ↗ |
| 69 | 2015 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer Timothy P. Coughlin Chief Financial Officer Christopher F. O’Brien, M.D. Chief Medical Officer Eric Benevich Chief Commercial Officer Haig P. Bozigian, Ph.D. Chief Development Officer | 472.8K | 236.4K | 395.9K | 1.61M | — | 27.1K | 2.74M | 73.17% | ↗ |
| 70 | 2015 | Haig P. Bozigian, Ph.D. Chief Development Officer | 381.6K | 190.8K | 362.9K | 1.40M | — | 39.0K | 2.37M | 74.22% | ↗ |
| 71 | 2015 | Timothy P. Coughlin Former Chief Financial Officer Christopher F. O’Brien, M.D. Former Chief Medical Officer Haig P. Bozigian, Ph.D. Chief Development Officer | 381.6K | 190.8K | 362.9K | 1.40M | — | 39.0K | 2.37M | 74.22% | ↗ |
| 72 | 2014 | Christopher F. O’Brien, M.D. Chief Medical Officer | 557.3K | 401.3K | 2.55M | 2.41M | — | 39.6K | 5.95M | 83.23% | ↗ |
| 73 | 2014 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer Timothy P. Coughlin Chief Financial Officer Christopher F. O’Brien, M.D. Chief Medical Officer Eric Benevich Chief Commercial Officer | 459.0K | 275.4K | 1.74M | 1.18M | — | 24.8K | 3.69M | 79.40% | ↗ |
| 74 | 2014 | Haig P. Bozigian, Ph.D. Chief Development Officer | 409.7K | 245.8K | 1.74M | 1.18M | — | 34.8K | 3.62M | 80.92% | ↗ |
| 75 | 2014 | Haig P. Bozigian, Ph.D. Chief Development Officer | 363.4K | 218.0K | 1.72M | 1.03M | — | 39.6K | 3.38M | 81.61% | ↗ |
| 76 | 2014 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer Timothy P. Coughlin Chief Financial Officer Christopher F. O’Brien, M.D. Chief Medical Officer Eric Benevich Chief Commercial Officer Haig P. Bozigian, Ph.D. Chief Development Officer | 363.4K | 218.0K | 1.72M | 1.03M | — | 39.6K | 3.38M | 81.61% | ↗ |
| 77 | 2013 | Christopher F. O’Brien, M.D. Chief Medical Officer | 541.1K | 178.6K | 259.5K | 1.09M | — | 38.8K | 2.11M | 64.05% | ↗ |
| 78 | 2013 | Timothy P. Coughlin Chief Financial Officer | 541.1K | 178.6K | 259.5K | 1.09M | — | 38.8K | 2.11M | 64.05% | ↗ |
| 79 | 2013 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer Timothy P. Coughlin Chief Financial Officer Christopher F. O’Brien, M.D. Chief Medical Officer Eric Benevich Chief Commercial Officer | 445.6K | 122.5K | 121.1K | 536.6K | — | 23.9K | 1.25M | 52.63% | ↗ |
| 80 | 2013 | Haig P. Bozigian, Ph.D. Chief Development Officer | 397.8K | 109.4K | 121.1K | 536.6K | — | 35.7K | 1.20M | 54.78% | ↗ |
| 81 | 2013 | Dimitri E. Grigoriadis, Ph.D. Chief Research Officer | 397.8K | 109.4K | 121.1K | 536.6K | — | 35.7K | 1.20M | 54.78% | ↗ |
| 82 | 2013 | Haig P. Bozigian, Ph.D. Chief Development Officer | 352.8K | 97.0K | 112.5K | 468.0K | — | 37.8K | 1.07M | 54.34% | ↗ |
| 83 | 2012 | Timothy P. Coughlin Chief Financial Officer | 525.3K | 220.6K | — | 1.50M | — | 42.6K | 2.28M | 65.47% | ↗ |
| 84 | 2012 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer | 525.3K | 220.6K | — | 1.50M | — | 42.6K | 2.28M | 65.47% | ↗ |
| 85 | 2012 | Haig P. Bozigian, Ph.D. Chief Development Officer | 432.6K | 151.4K | — | 747.6K | — | 26.1K | 1.36M | 55.07% | ↗ |
| 86 | 2012 | Dimitri E. Grigoriadis, Ph.D. Chief Research Officer | 386.3K | 135.2K | — | 747.6K | — | 36.5K | 1.31M | 57.26% | ↗ |
| 87 | 2012 | Christopher F. O’Brien, M.D. Chief Medical Officer | 386.3K | 135.2K | — | 747.6K | — | 36.5K | 1.31M | 57.26% | ↗ |
| 88 | 2011 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer | 510.0K | 198.9K | — | 1.03M | — | 44.8K | 1.78M | 57.63% | ↗ |
| 89 | 2011 | Timothy P. Coughlin Chief Financial Officer | 510.0K | 198.9K | — | 1.03M | — | 44.8K | 1.78M | 57.63% | ↗ |
| 90 | 2011 | Christopher F. O’Brien, M.D. Senior Vice President, Clinical Development and Chief Medical Officer | 510.0K | 198.9K | — | 1.03M | — | 44.8K | 1.78M | 57.63% | ↗ |
| 91 | 2011 | Haig P. Bozigian, Ph.D. Chief Development Officer | 420.0K | 136.5K | — | 512.5K | — | 26.3K | 1.10M | 46.79% | ↗ |
| 92 | 2011 | Haig P. Bozigian, Ph.D. Senior Vice President, Pharmaceutical and Preclinical Development | 375.0K | 121.9K | — | 512.5K | — | 34.0K | 1.04M | 49.12% | ↗ |
| 93 | 2011 | Christopher F. O’Brien, M.D. Chief Medical Officer | 375.0K | 121.9K | — | 512.5K | — | 34.0K | 1.04M | 49.12% | ↗ |
| 94 | 2011 | Dimitri E. Grigoriadis, Ph.D. Chief Research Officer | 375.0K | 121.9K | — | 512.5K | — | 34.0K | 1.04M | 49.12% | ↗ |
| 95 | 2010 | Timothy P. Coughlin Vice President and Chief Financial Officer | 440.0K | 396.0K | — | 325.6K | — | 31.6K | 1.19M | 27.29% | ↗ |
| 96 | 2010 | Margaret Valeur-Jensen, Ph.D., J.D. Executive Vice President, General Counsel and Secretary | 440.0K | 396.0K | — | 325.6K | — | 31.6K | 1.19M | 27.29% | ↗ |
| 97 | 2010 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer | 440.0K | 396.0K | — | 325.6K | — | 31.6K | 1.19M | 27.29% | ↗ |
| 98 | 2010 | Margaret Valeur-Jensen, Ph.D., J.D. Former Executive Vice President, General Counsel, Corporate Secretary | 375.0K | 300.0K | — | 299.2K | — | 16.9K | 991.1K | 30.19% | ↗ |
| 99 | 2010 | Haig P. Bozigian, Ph.D. Chief Development Officer | 375.0K | 300.0K | — | 299.2K | — | 16.9K | 991.1K | 30.19% | ↗ |
| 100 | 2010 | Christopher F. O’Brien, M.D. Chief Medical Officer | 300.0K | 240.0K | — | 299.2K | — | 23.6K | 862.8K | 34.68% | ↗ |
| 101 | 2010 | Dimitri E. Grigoriadis, Ph.D. Vice President of Research | 300.0K | 240.0K | — | 299.2K | — | 23.6K | 862.8K | 34.68% | ↗ |
| 102 | 2009 | Margaret Valeur-Jensen, Ph.D., J.D. Executive Vice President, General Counsel and Secretary Christopher F. O’Brien, M.D. Senior Vice President, Clinical Dimitri E. Grigoriadis, Ph.D. Vice President of Research Haig P. Bozigian, Ph.D. Senior Vice President, Pharmaceutical | 440.0K | — | — | — | — | 293.1K | 733.1K | 0.00% | ↗ |
| 103 | 2009 | Timothy P. Coughlin Vice President and Chief Financial Officer | 440.0K | — | — | — | — | 34.6K | 474.6K | 0.00% | ↗ |
| 104 | 2009 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer | 440.0K | — | — | — | — | 34.6K | 474.6K | 0.00% | ↗ |
| 105 | 2009 | Haig P. Bozigian, Ph.D. Senior Vice President, Pharmaceutical | 395.0K | — | — | — | — | 27.9K | 422.9K | 0.00% | ↗ |
| 106 | 2009 | Haig P. Bozigian, Ph.D. Senior Vice President, Pharmaceutical and Preclinical Development | 375.0K | — | — | — | — | 19.8K | 394.8K | 0.00% | ↗ |
| 107 | 2009 | Christopher F. O’Brien, M.D. Senior Vice President, Clinical Development and Chief Medical Officer | 300.0K | — | — | — | — | 25.0K | 325.0K | 0.00% | ↗ |
| 108 | 2008 | Margaret Valeur-Jensen, J.D., Ph.D. Executive Vice President, General Counsel and Secretary Christopher F. O’Brien, M.D. Senior Vice President, Clinical Development and Chief Medical Officer Dimitri E. Grigoriadis, Ph.D. Vice President of Research Haig P. Bozigian, Ph.D. Senior Vice President, Pharmaceutical and Preclinical Development | 440.0K | 240.0K | 431.6K | — | — | 30.5K | 1.52M | 28.40% | ↗ |
| 109 | 2008 | Timothy P. Coughlin Vice President and Chief Financial Officer | 440.0K | 240.0K | 640.0K | 131.9K | — | 30.5K | 1.48M | 52.07% | ↗ |
| 110 | 2008 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer | 440.0K | 240.0K | 640.0K | 131.9K | — | 30.5K | 1.48M | 52.07% | ↗ |
| 111 | 2008 | Dimitri E. Grigoriadis, Ph.D. Vice President of Research | 395.0K | 190.0K | 512.0K | 87.9K | — | 26.1K | 1.21M | 49.54% | ↗ |
| 112 | 2008 | Margaret Valeur-Jensen, Ph.D., J.D. Executive Vice President, General Counsel and Secretary | 300.0K | 137.5K | 512.0K | 87.9K | — | 22.9K | 1.06M | 56.58% | ↗ |
| 113 | 2007 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer | 400.0K | — | 720.7K | 717.1K | — | 18.1K | 1.86M | 77.47% | ↗ |
| 114 | 2007 | Margaret Valeur-Jensen, Ph.D., J.D. Executive Vice President, General Counsel and Secretary Christopher F. O’Brien, M.D. Senior Vice President, Clinical Dimitri E. Grigoriadis, Ph.D. Vice President of Research Haig P. Bozigian, Ph.D. Senior Vice President, Pharmaceutical | 275.0K | — | 663.5K | 664.0K | — | 10.1K | 1.61M | 82.32% | ↗ |
| 115 | 2007 | Timothy P. Coughlin Vice President and Chief Financial Officer | 400.0K | — | 258.9K | — | — | 18.1K | 1.19M | 21.76% | ↗ |
| 116 | 2007 | Gary A. Lyons Former President and Chief Executive Officer | 275.0K | — | 221.2K | — | — | 10.1K | 775.0K | 28.54% | ↗ |
| 117 | 2007 | Margaret Valeur-Jensen, J.D., Ph.D. Executive Vice President, General Counsel and Secretary | 275.0K | — | 221.2K | — | — | 10.1K | 775.0K | 28.54% | ↗ |
| 118 | 2006 | Gary A. Lyons President and Chief Executive Officer | 600.0K | — | 1.24M | — | — | 10.5K | 3.49M | 35.45% | ↗ |
| 119 | 2006 | Paul W. Hawran Former Executive Vice President and Chief Financial Officer | 365.0K | — | 246.1K | — | — | 9.4K | 1.21M | 20.42% | ↗ |
| 120 | 2006 | Margaret Valeur-Jensen, J.D., Ph.D. Executive Vice President, General Counsel and Secretary | 348.1K | 115.0K | 95.2K | — | — | 8.6K | 942.2K | 10.10% | ↗ |
| 121 | 2006 | Richard Ranieri Senior Vice President, Human Resources | 287.0K | 120.0K | 37.2K | — | — | 43.8K | 859.0K | 4.34% | ↗ |
| 122 | 2006 | Gary A. Lyons Former President and Chief Executive Officer | 287.0K | 120.0K | 37.2K | — | — | 43.8K | 859.0K | 4.34% | ↗ |
| 123 | 2006 | Kevin C. Gorman, Ph.D. President and Chief Executive Officer | 339.8K | — | 102.1K | — | — | 7.7K | 847.1K | 12.05% | ↗ |
| 124 | 2006 | Kevin C. Gorman, Ph.D. Executive Vice President and Chief Operating Officer | 339.8K | — | 102.1K | — | — | 7.7K | 847.1K | 12.05% | ↗ |
| 125 | 2006 | Kevin C. Gorman, Ph.D President and Chief Executive Officer | 339.8K | — | 102.1K | — | — | 7.7K | 847.1K | 12.05% | ↗ |
| 126 | 2006 | Wendell Wierenga, Ph.D. Former Executive Vice President, Research and Development | 385.0K | — | 128.9K | — | — | 16.1K | 822.1K | 15.67% | ↗ |
| 127 | 2006 | Richard Ranieri Senior Vice President and Chief Administrative Officer | 220.5K | 75.0K | — | — | — | 6.9K | 434.8K | 0.00% | ↗ |
| 128 | 2006 | Margaret Valeur-Jensen, J.D., Ph.D. Executive Vice President, General Counsel and Secretary Christopher F. O’Brien, M.D. Senior Vice President, Clinical Development and Chief Medical Officer Dimitri E. Grigoriadis, Ph.D. Vice President of Research Haig P. Bozigian, Ph.D. Senior Vice President, Pharmaceutical and Preclinical Development | 220.5K | 75.0K | — | — | — | 6.9K | 434.8K | 0.00% | ↗ |
| 129 | 2006 | Timothy P. Coughlin Vice President and Chief Financial Officer | 220.5K | 75.0K | — | — | — | 6.9K | 434.8K | 0.00% | ↗ |
| 130 | 2005 | Gary A. Lyons President and Chief Executive Officer | 547.0K | — | — | — | — | 8.4K | 555.4K | 0.00% | ↗ |
| 131 | 2005 | Wendell Wierenga, Ph.D. Executive Vice President Research and Development | 350.0K | — | — | — | — | 8.2K | 358.2K | 0.00% | ↗ |
| 132 | 2005 | Paul W. Hawran Executive Vice President and Chief Financial Officer | 325.0K | — | — | — | — | 8.2K | 333.2K | 0.00% | ↗ |
| 133 | 2005 | Margaret Valeur-Jensen, J.D., Ph.D. Executive Vice President, General Counsel and Secretary | 300.0K | — | — | — | — | 8.1K | 308.1K | 0.00% | ↗ |
| 134 | 2005 | Kevin C. Gorman Executive Vice President and Chief Business Officer | 292.0K | — | — | — | — | 8.1K | 300.1K | 0.00% | ↗ |
| 135 | 2004 | Gary A. Lyons President and Chief Executive Officer | 510.0K | 220.6K | — | — | — | 8.2K | 738.8K | 0.00% | ↗ |
| 136 | 2004 | Gary A. Lyons President and Chief Executive Officer Executive Vice President and Chief Financial Officer Executive Vice President, Clinical Development Chief Medical Officer Research and Development Senior Vice President, Commercial Operations | 510.0K | 220.6K | — | — | — | — | 730.6K | 0.00% | ↗ |
| 137 | 2004 | Kevin C. Gorman Executive Vice President and Chief Business Officer | 278.0K | 110.3K | — | — | — | 7.9K | 396.2K | 0.00% | ↗ |
| 138 | 2004 | Margaret Valeur-Jensen, J.D., Ph.D. Executive Vice President, General Counsel and Secretary | 286.0K | 82.7K | — | — | — | 7.9K | 376.6K | 0.00% | ↗ |
| 139 | 2004 | Paul W. Hawran Executive Vice President and Chief Financial Officer | 312.0K | 55.2K | — | — | — | 8.0K | 375.1K | 0.00% | ↗ |
| 140 | 2004 | Wendell Wierenga, Ph.D. Executive Vice President Research and Development | 309.0K | — | — | — | — | 8.0K | 317.0K | 0.00% | ↗ |
| 141 | 2003 | Gary A. Lyons President and Chief Executive Officer | 475.0K | 169.8K | — | — | — | 8.1K | 652.9K | 0.00% | ↗ |
| 142 | 2003 | Gary A. Lyons President and Chief Executive Officer Executive Vice President and Chief Financial Officer Executive Vice President, Clinical Development Chief Medical Officer Research and Development Senior Vice President, Commercial Operations | 475.0K | 169.8K | — | — | — | — | 644.8K | 0.00% | ↗ |
| 143 | 2003 | Henry Y. Pan, M.B.B.S., Ph.D., F.A.C.C. Executive Vice President, Clinical Development Chief Medical Officer | 330.0K | 24.3K | — | 20.0K | — | 136.1K | 490.3K | 4.08% | ↗ |
| 144 | 2003 | Kevin C. Gorman Executive Vice President and Chief Business Officer | 265.0K | 97.0K | — | — | — | 7.7K | 369.7K | 0.00% | ↗ |
| 145 | 2003 | Kevin C. Gorman, Ph.D. Senior Vice President, Business Development | 265.0K | 97.0K | — | 40.0K | — | 6.0K | 368.0K | 10.87% | ↗ |
| 146 | 2003 | Wendell Wierenga, Ph.D. Executive Vice President Research and Development | 100.0K | 260.7K | — | — | — | 3.7K | 364.5K | 0.00% | ↗ |
| 147 | 2003 | Paul W. Hawran Executive Vice President and Chief Financial Officer | 298.0K | 48.5K | — | — | — | 7.8K | 354.3K | 0.00% | ↗ |
| 148 | 2003 | Margaret Valeur-Jensen, J.D., Ph.D. Executive Vice President, General Counsel and Secretary | 272.0K | 72.8K | — | — | — | 7.7K | 352.5K | 0.00% | ↗ |
| 149 | 2003 | Margaret E. Valeur-Jensen, J.D., Ph.D. Senior Vice President, General Counsel and Secretary | 272.0K | 72.8K | — | 35.0K | — | 6.0K | 350.8K | 9.98% | ↗ |
| 150 | 2002 | Henry Y. Pan, M.B.B.S., Ph.D., F.A.C.C. Executive Vice President, Clinical Development Chief Medical Officer | 315.0K | — | — | — | — | 276.6K | 591.6K | 0.00% | ↗ |
| 151 | 2002 | Gary A. Lyons President and Chief Executive Officer | 437.0K | — | — | 125.0K | — | 5.5K | 442.5K | 28.25% | ↗ |
| 152 | 2002 | Gary A. Lyons President and Chief Executive Officer Executive Vice President and Chief Financial Officer Executive Vice President, Clinical Development Chief Medical Officer Research and Development Senior Vice President, Commercial Operations | 437.0K | — | — | — | — | — | 437.0K | 0.00% | ↗ |
| 153 | 2002 | Paul W. Hawran Executive Vice President and Chief Financial Officer | 284.0K | — | — | 40.0K | — | 5.5K | 289.5K | 13.82% | ↗ |
| 154 | 2002 | Margaret E. Valeur-Jensen, J.D., Ph.D. Senior Vice President, General Counsel and Secretary | 259.0K | — | — | 35.0K | — | 5.5K | 264.5K | 13.23% | ↗ |
| 155 | 2002 | Kevin C. Gorman, Ph.D. Senior Vice President, Business Development | 229.6K | — | — | 35.0K | — | 5.5K | 235.1K | 14.89% | ↗ |
| 156 | 2002 | D. Bruce Campbell, Ph.D Senior Vice President, International Development | — | — | — | — | — | — | — | — | ↗ |
| 157 | 2002 | Henry Y. Pan, M.B.B.S., Ph.D., F.A.C.C Executive Vice President, | — | — | — | — | — | — | — | — | ↗ |
| 158 | 2002 | Margaret E. Valeur-Jensen, J.D., Ph.D Senior Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 159 | 2001 | Gary A. Lyons President and Chief Executive Officer | 405.0K | — | — | 100.0K | — | 5.3K | 410.3K | 24.38% | ↗ |
| 160 | 2001 | Paul W. Hawran Executive Vice President and Chief Financial Officer | 273.0K | — | — | — | — | 5.3K | 278.3K | 0.00% | ↗ |
| 161 | 2001 | Margaret E. Valeur-Jensen, J.D., Ph.D. Senior Vice President, General Counsel and Secretary | 247.0K | — | — | 35.0K | — | 5.3K | 252.3K | 13.88% | ↗ |
| 162 | 2001 | Kevin C. Gorman, Ph.D. Senior Vice President, Business Development | 185.0K | — | — | 30.0K | — | 4.0K | 189.0K | 15.87% | ↗ |
| 163 | 2001 | Henry Y. Pan, M.B.B.S., Ph.D., F.A.C.C. Executive Vice President, Clinical Development Chief Medical Officer | 65.6K | — | — | 200.0K | — | 8.8K | 74.4K | 268.75% | ↗ |
| 164 | 2001 | Margaret E. Valeur-Jensen, J.D., Ph.D Senior Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 165 | 2001 | D. Bruce Campbell, Ph.D Senior Vice President, International Development | — | — | — | — | — | — | — | — | ↗ |
| 166 | 2001 | Henry Y. Pan, M.B.B.S., Ph.D., F.A.C.C Executive Vice President, | — | — | — | — | — | — | — | — | ↗ |
| 167 | 2000 | Margaret E. Valeur-Jensen, J.D., Ph.D Senior Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 168 | 2000 | D. Bruce Campbell, Ph.D Senior Vice President, International Development | — | — | — | — | — | — | — | — | ↗ |
| 169 | 2000 | Gary A. Lyons President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 170 | 2000 | Paul W. Hawran Executive Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kyle W. Gano | President, CEO & Director | 2M | male |
| Jude Onyia | Chief Scientific Officer | 1M | — |
| Eiry Wyn Roberts | Strategic Advisor | 1M | — |
| Matthew C. Abernethy | Chief Financial Officer | 1M | male |
| Eric S. Benevich | Chief Commercial Officer | 1M | male |
| Sanjay Keswani MBBS | Chief Medical Officer | 1M | — |
| Darin Lippoldt | Chief Legal Officer & Corporate Secretary | 921.0K | male |
| Wylie W. Vale | Co-Founder | 47.0K | — |
| Lawrence Steinman | Co-Founder of Neurocrine | — | — |
| Lewis Choi | Chief Information Officer | — | male |
| Ingrid Delaet | Chief Regulatory Officer | — | — |
| Julie S. Cooke | Chief Human Resources Officer | — | female |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-06-17 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-06-11 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2024-11-19 | 2024-12-18 | Michael McCaul | TX10 | Spouse | Sale | $15,001 - $50,000 | ↗ |
| 2024-08-26 | 2024-09-18 | Michael McCaul | TX10 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-10-27 | 2023-11-17 | Michael McCaul | TX10 | Spouse | Sale | $50,001 - $100,000 | ↗ |
| 2023-10-27 | 2023-11-17 | Michael McCaul | TX10 | — | Sale | $15,001 - $50,000 | ↗ |
| 2023-08-14 | 2023-09-20 | Michael McCaul | TX10 | Spouse | Purchase | $50,001 - $100,000 | ↗ |
| 2023-08-14 | 2023-09-20 | Michael McCaul | TX10 | — | Purchase | $15,001 - $50,000 | ↗ |
| 2023-05-02 | 2023-06-22 | Michael McCaul | TX10 | — | Sale | $15,001 - $50,000 | ↗ |
| 2023-02-10 | 2023-03-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2022-12-16 | 2023-01-20 | Michael McCaul | TX10 | — | Sale | $1,001 - $15,000 | ↗ |
| 2022-12-06 | 2023-01-03 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-01-28 | 2022-02-23 | Michael McCaul | TX10 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2021-12-21 | 2022-01-27 | Michael McCaul | TX10 | Spouse | Sale | $15,001 - $50,000 | ↗ |
| 2021-12-14 | 2022-01-27 | Michael McCaul | TX10 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2021-03-09 | 2021-04-19 | Michael McCaul | TX10 | Self | Purchase | $15,001 - $50,000 | ↗ |
| 2020-12-21 | 2021-01-11 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2020-07-21 | 2020-08-19 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NBIX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
